Comprar Barato Online Maxicardil, Maxicardil

Comprar Maxicardil

Erstmals ist muxol moglich, die unmittelbare Entstehung des Menschen im Labor zu beobachten oder sogar an ihr zu experimentieren.

Dabei eroffnen sich Perspektiven, die den meisten Arzten feldegel des moglichen Missbrauchs gro?es Unbehagen bereiten.

Tags relacionados: Maxicardil (dipyridamole) precios de la pildora Maxicardil Maxicardil (dipyridamole) 100 mg de bajo coste Maxicardil (dipyridamole) 100/25 mg precios baratos Maxicardil (dipyridamole) visa, mastercard Maxicardil (dipyridamole) 100 mg venta en farmacias Maxicardil los precios mas baratos Maxicardil (dipyridamole) precios de pastillas Maxicardil (dipyridamole) 25 mg comprar barato Maxicardil precios de pastillas Compara precios de medicamentos maxicardil (dipyridamole) 25 mg Maxicardil comprar pela internet Maxicardil comprar sin receta Pastillas maxicardil 100 mg Maxicardil no prescripcion Pastillas maxicardil (dipyridamole) 25 mg Descuento de precios maxicardil (dipyridamole) 100 mg Comprar barato online maxicardil (dipyridamole) 100 mg Maxicardil (dipyridamole) 100 mg descuento online Comprar maxicardil Maxicardil 25 mg compra venta online Pastillas maxicardil 100/25 mg Maxicardil (dipyridamole) 100 mg compra venta online Generico maxicardil (dipyridamole) 25 mg Maxicardil (dipyridamole) 100/25 mg india farmaceutico de formulaciones Costo promedio maxicardil 100/25 mg Maxicardil 100 mg baratos sin receta generic Medicamentos maxicardil (dipyridamole) 100 mg Maxicardil (dipyridamole) 25 mg los precios mas baratos Maxicardil 100/25 mg venta en farmacias Costo promedio maxicardil Maxicardil (dipyridamole) 100 mg precios de los medicamentos Maxicardil 25 mg baratos sin receta generic Maxicardil 25 mg precios de la pildora Maxicardil (dipyridamole) 100/25 mg comprar online Maxicardil 100/25 mg farmacia online Maxicardil 25 mg comprar sin receta Maxicardil (dipyridamole) 25 mg baratos sin receta generic Maxicardil (dipyridamole) 25 mg baratos sin receta Maxicardil (dipyridamole) precios de los medicamentos

Articulos de interes:

Buscar/Search/Chercher:

Donde/Where/Ou

Bendit, planchas de asar.

Mosen Cinto Verdaguer, 3 25100 Almacelles (Lleida) Tel. (34) 973 26 93 96 bendit@bendit. es www. bendit. es

Dermasil Dry Skin Treatment - Original Lotion, Cures And Beautifies Even Severe Dry Skin, Dermasil

Dermasil Dry Skin Treatment - Original Lotion Treats and Beautifies Even Severe Dry Skin

8oz Dermasil Lotion for Dry Skin Treatment - Original, Table Size 16oz Dermasil Lotion for Dry Skin Treatment - Original, Family size

Dermasil Labs has developed Dermasil OTC pharmaceutical skin care, a powerful dry skin treatment and skin protectant.

This lotion contains 4 systems to control and provide long-lasting relief from severe dry skin:

Occlusives to block moisture loss from the skin's surface Humectant to bind water in the skin's outermost layers Skin Lipids to enhance the skin's natural ability to retain moisture EFA's an important component of the skin's moisture barrier

Indications Suitable for severe dry skin, and control of symptoms such as chapping, cracking, flaking, roughness, redness, soreness, and the itching associated with dry skin.

Recommendations Apply Dermasil every day to hands and body as needed or as directed by physician. Also available in Sensitive and Advanced Treatment.

Active Ingredient Dimethicone

Inactive Ingredients Water, Glycerin, Petrolatum, Mineral Oil (Paraffinum Liquidum), Stearic Acid, Glycol Stearate, Glyceryl Stearate, PEG-40 Stearate, Cetyl Alcohol, Cetyl Acetate, Sodium Hydroxide, Phenoxyethanol, Carbomer, Helianthus Annuus (Sunflower) Seed Oil, Disodium EDTA, Acetylated Lanolin Alcohol, Geranium Maculatum Oil, Methylisothiazolinone, Iodopropynyl Butylcarbamate, Magnesium Aluminum Silicate, Lecithin, Borago Officinalis Seed Oil, Cholesterol, Ascorbyl Palmitate, Prunus Amygdalus Dulcis (Sweet Almond) Oil, Ethylene Brassylate, Santalum Album (Sandalwood) Oil, Rosa Damascena Extract, Vanilla Planifolia Fruit Extract

Warning Keep out of reach of children. For external use only. Avoid contact with eyes. If condition worsens or does not improve within 7 days, consult a doctor or pharmacist. Not to be applied over deep or puncture wounds, infections or lacerations.

Material Safety Data Sheet (MSDS)

Meet Gudrun Penselin, Penselin

Meet Gudrun Penselin

“I see Gudrun as a healer and friend to those around her and the Earth itself, and am constantly inspired to strengthen my own commitment to living a life based in Love, and the singular dedication to the much needed healing of this Earth and its people.” .

– Lana Robinson, B. A. (Psychology and Political Science); Presiding Clerk of Canadian Friends Service Committee (CFSC); Community Health Organizer

I was born and raised in Germany and like so many children back then we played outside much of the time. Preventative health in the form of healthy lifestyle choices was an integral part of my upbringing. When we did get sick my mother’s first line of defense was inspired by common sense and her own inner wisdom. Instead of running to the medicine chest to give us a pill or taking us to the doctor (unless absolutely necessary) her secret was wholesome foods, herbal teas, lots of rest and fresh air. This simple form of treatment was successful most of the time which means that to this date I hardly ever have had to rely on medication or conventional medicine to get and be well.

When I was about 12 years old we made a decision as a family that had far reaching consequences for me. Instead of buying Christmas presents we decided to sponsor a child in India on a long-term basis. I was in charge of the correspondence with the child and several years of writing letters back and forth created a strong desire to travel to India. I decided to spend half a year in India after completing high school and before entering university.

While planning my trip I happened to watch a television show about Mother Teresa and her work in Calcutta. I felt so inspired that I decided to write to her asking if I could spend some time with her. She replied with an invitation to visit the Missionaries of Charity. During my travels in India I spent time with Mother Teresa in Calcutta primarily helping with orphaned infants. Mother Theresa worked with the heart and soul of people, with compassion and non-judgment. “If you judge people, you have no time to love them.” My experience with her and my remaining time spent in India has changed my life and continues to inspire me to live my life in service to the Earth and its people.

Back in Germany I completed my post-secondary education with a M. Education and M. Physical Education. In 1981 I emigrated to Canada where I raised my three beautiful children “the natural way” in the country of northern Alberta, home schooling them whenever they desired for a total of 13 years. Since moving to Canada I have focused my professional education on complementary medicine including more recently traditional forms of Mexican healing. For over 30 years now I have been running a successful practice in Grande Prairie, Alberta. I uniquely integrate various methods of healing such as herbal medicine, reflexology, Bach Flowers, iridology, sclerology, light & colour therapy, EFT (Emotional Freedom Technique), bio-feedback and lifestyle improvement. Over the years I have helped thousands of people through my teachings and my practice by using my holistic approach to wellness, always considering all aspects – emotional, spiritual, physical and mental.

My joy and passion is to encourage others on their healing journey and support them in unfolding to their full potential. I am filled with gratitude when I watch my clients and students leave my office feeling empowered and stronger, filled with hope and carrying a big smile on their face.

I have given public talks and taught workshops in Canada and the US and am now a featured guest on international radio interviews. I offer workshops in all the healing arts that I utilize in my practice. My classes are experiential and interactive, with a focus on practicality and fun.

I look on the Earth as our Mother who provides for us with unconditional love regardless of the abuse by the human race. In my practice and teachings I re-awaken in people this awareness and the connection to the Earth, a prerequisite for the healing of the planet and humankind. Due to my own strong connection with the Earth people are able to experience the spirit of plants and how the plants can serve us as teachers, guides and friends.

I also believe in the healing potential of the Bach Flowers and in 1998 I created Bach Flowers Unfolding, an innovative publication. The second edition is about to be released. In 2012 I produced the instructional DVD Herbal Pharmacy for Everyone, A Step-by–Step Guide to Creating Your Own Herbal Preparations. I have dedicated the DVD to the children of the Earth because they are our future.

“The flowers of tomorrow are in the seeds of today.” – Author Unknown

I look forward to sharing my knowledge and experience with you, be it in the form of a consultation, speaking engagement or workshops. Please contact me for further information.

Contact Information

Gudrun Penselin, M. Ed. M. Phys. Ed Clinical Herbal Therapist, Certified Reflexologist, Bach Flower Practitioner, Certified Iridologist, Sclerologist, Light & Colour Therapist Over 30 years of experience as a practitioner, teacher and speaker.

Solunac, Solunac

Solunac

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Dronactin - Drug Review Dosage, Side Effects, Action, Buy Dronactin, Dronactin

Dronactin

Dronactin is a multi-use medication that is prescribed mostly for patients with allergies. specifically hay fever. and patients suffering from anorexia. It relieves the sneezing. itching. bloating and watery eyes induced by most allergies.

DRONACTIN ACTION

This medication is an anti-histamine with antagonistic tendencies toward serotonin in the body. This means that this medication stops the different chemicals in the body that cause allergic reactions. usually through blood flow control and blood vessel constrictions. The change in serotonin levels affects one’s mood, so the anorexia is challenged by Dronactin through its antagonistic strategy against serotonin. Dronactin is also used to battle insomnia because of its unusually strong sedative effects as an anti-histamine.

DRONACTIN SIDE EFFECTS

Some common side effects of Dronactin include nausea. vomiting. headaches. hypertension. diarrhea. chest pains, dry mouth. confusion. scratchy throat, and a loss of appetite. Serious side effects that may be a sign of an allergic reaction include intense excitement, rashes, problems with vision, difficulty urinating, and weakness in the body. Consult your doctor immediately if any of these side effects occur. It might be best to bring Dronactin patients to a hospital if they show even the slightest sign of an allergic reaction to the medication.

DRONACTIN PRECAUTIONS

Before taking Dronactin there are some precautionary measurements that each person should take. First, inform your doctor of any medications, over the counter or prescription, that you are taking. Specifically, you should reveal if you are taking cold medicine, depression medicine, sleeping pills, muscle relaxants, narcotics and even vitamins. Second, inform your doctor about any illnesses you have previously contracted. Asthma. diabetes. hyperthyroidism. urinary tract disorders, heart disease, high blood pressure and seizures can all affect Dronactin and how it affects your body. Adult Dronactin patients should remember that Dronactin specifically has a strong sedative effect so driving or operating machinery that can harm others is not suggested especially after first taking the medication. The medication has the opposite effect on young children. While adults may feel drowsy after taking Dronactin, children, especially very young children, tend to become excited and very active.

DRONACTIN DURING PREGNANCY

Pregnant women should be careful about using this medication since it has not been proved safe for fetuses yet. There might be some risk of abnormalities in the fetus; however it has not been proven yet. It’s better to inform your doctor and have him adjust the dosage or maybe give you another medication. Nursing mothers should be careful too since this medication might pass through the breast milk. It has been suggested that it would be better to stop breastfeeding while on Dronactin, since most medications are passed on in breast milk.

DRONACTIN DOSAGE

This medication is marketed as Periactin and the dosage being administered varies according to the patient’s age and body mass. For children, the doses vary from 2- 16 mg a day. Adults may use 4-20 mg per day as prescribed by treating doctor. Patients are usually directed to take one pill during various times of the day. This is a medication that can be taken without food.

Dronactin has the following structural formula:

Molecular formula of dronactin is C21H21N Molecular weight is 287.398 g/mol Dronactin available. 2mg/5ml syrup, 4mg tablets

Diabetex™ Archives, Diabetex

Diabetex is a unique line of supplements that provide nutritional support and risk reduction for people with type 2 diabetes. Developed by our doctors who specialize in blood glucose management, the Diabetex product line is uniquely designed to support key aspects of health. Good nutrition, exercise, and nutritional supplements can have a positive impact on the prevention and management of type 2 diabetes and pre-diabetic conditions.

Diabetex™ Multi Vitamin

A vitamin and mineral dietary supplement specifically formulated to support healthy blood sugar balance

Diabetex™ PGX® with Mulberry

PGX helps reduce appetite and cravings, to support normal blood glucose and cholesterol levels.

Diabetex™ Sleep Support Melatonin 3 mg, L-Theanine & 5-HTP

A combination of some of nature's best sleep "supporters", 5-HTP, melatonin, and L-theanine.

Diabetex™ Eye Care 10 mg Lutein

A protective formula with 10 mg of antioxidant Lutein to support eye health.

Dexamethasone In Reducing Oral Pain And Dry Mouth After Surgery In Patients With Oropharyngeal Cance

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Supportive Care

A Randomized, Placebo Controlled, Double Blinded Study of Corticosteroid Treatment for the Reduction of Postoperative Pain Following Transoral Robotic Surgery

Resource links provided by NLM:

Further study details as provided by OHSU Knight Cancer Institute:

Primary Outcome Measures:

Pain visual analogue scale (VAS) score measured at 10-point scale [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

A descriptive time plot of VAS scores will be produced for all enrolled subjects, with loess curve fitted separately for the experimental and control groups. A linear mixed effects model will be used to compare the pain VAS scores between the experimental and control groups.

Secondary Outcome Measures:

Complications associated with postoperative corticosteroid use after TORS [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]

A descriptive statistical analysis will be conducted on complications.

Eating Assessment Tool (EAT)-10 scores [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

A descriptive time plot will be produced for EAT-10 scores using baseline and postoperative measurements on days 3 and day 7-21. Descriptive statistical analyses will be conducted for a summary of EAT-10 scores at baseline, days 3 and day 7-21 after surgery. A linear mixed effects model will be used to compare the EAT-10 scores between the two groups.

Length of hospital stay (number of days between the date of surgery and date of discharge) [ Time Frame: Up to 21 days ] [ Designated as safety issue: No ]

Kaplan-Meier functions will be fitted to compare the length of hospital stay between the experimental and control groups.

Experimental: Arm I (treatment)

Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.

Other Names:

Aacidexam

Adexone

Aknichthol Dexa

Alba-Dex

Alin

Alin Depot

Alin Oftalmico

Amplidermis

Anemul mono

Auricularum

Auxiloson

Baycuten

Baycuten N

Cortidexason

Cortisumman

Decacort

Decadrol

Decadron

Decalix

Decameth

Decasone R. p.

Dectancyl

Dekacort

Deltafluorene

Deronil

Desamethasone

Desameton

Dexa-Mamallet

Dexa-Rhinosan

Dexa-Scheroson

Dexa-sine

Dexacortal

Dexacortin

Dexafarma

Dexafluorene

Dexalocal

Dexamecortin

Dexameth

Dexamethasonum

Dexamonozon

Dexapos

Dexinoral

Dexone

Dinormon

Fluorodelta

Fortecortin

Gammacorten

Hexadecadrol

Hexadrol

Lokalison-F

Loverine

Methylfluorprednisolone

Millicorten

Mymethasone

Orgadrone

Spersadex

Visumetazone

Other Names:

Aacidexam

Adexone

Aknichthol Dexa

Alba-Dex

Alin

Alin Depot

Alin Oftalmico

Amplidermis

Anemul mono

Auricularum

Auxiloson

Baycuten

Baycuten N

Cortidexason

Cortisumman

Decacort

Decadrol

Decadron

Decalix

Decameth

Decasone R. p.

Dectancyl

Dekacort

Deltafluorene

Deronil

Desamethasone

Desameton

Dexa-Mamallet

Dexa-Rhinosan

Dexa-Scheroson

Dexa-sine

Dexacortal

Dexacortin

Dexafarma

Dexafluorene

Dexalocal

Dexamecortin

Dexameth

Dexamethasonum

Dexamonozon

Dexapos

Dexinoral

Dexone

Dinormon

Fluorodelta

Fortecortin

Gammacorten

Hexadecadrol

Hexadrol

Lokalison-F

Loverine

Methylfluorprednisolone

Millicorten

Mymethasone

Orgadrone

Spersadex

Visumetazone

Procedure: Quality-of-Life Assessment

Other Name: Quality of Life Assessment

Other: Questionnaire Administration

Procedure: Transoral Robotic Surgery

Other Name: TORS

Active Comparator: Arm II (control)

Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.

Other Names:

Aacidexam

Adexone

Aknichthol Dexa

Alba-Dex

Alin

Alin Depot

Alin Oftalmico

Amplidermis

Anemul mono

Auricularum

Auxiloson

Baycuten

Baycuten N

Cortidexason

Cortisumman

Decacort

Decadrol

Decadron

Decalix

Decameth

Decasone R. p.

Dectancyl

Dekacort

Deltafluorene

Deronil

Desamethasone

Desameton

Dexa-Mamallet

Dexa-Rhinosan

Dexa-Scheroson

Dexa-sine

Dexacortal

Dexacortin

Dexafarma

Dexafluorene

Dexalocal

Dexamecortin

Dexameth

Dexamethasonum

Dexamonozon

Dexapos

Dexinoral

Dexone

Dinormon

Fluorodelta

Fortecortin

Gammacorten

Hexadecadrol

Hexadrol

Lokalison-F

Loverine

Methylfluorprednisolone

Millicorten

Mymethasone

Orgadrone

Spersadex

Visumetazone

Other Names:

placebo therapy

PLCB

sham therapy

Procedure: Quality-of-Life Assessment

Other Name: Quality of Life Assessment

Other: Questionnaire Administration

Procedure: Transoral Robotic Surgery

Other Name: TORS

I. To prospectively determine if a longer 4-day course of dexamethasone (or equivalent) for the management of postoperative pain and dysphagia following transoral robotic surgery (TORS) is superior to the current standard of a single injection of dexamethasone 10 mg.

I. Determine the effect of postoperative corticosteroids on postoperative dysphagia following TORS.

II. Determine the effect of postoperative corticosteroids on length of hospital stay following TORS.

III. Determine the complications associated with postoperative corticosteroid use after TORS.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive dexamethasone intravenously (IV) at the time of surgery and orally (PO) every 8 hours for up to 4 days following surgery.

ARM II: Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.

After completion of study treatment, patients are followed up for up to 12 months.

Patients must be diagnosed with oropharyngeal squamous cell carcinoma (SCC) that are surgical candidates

Macroscopic resection of the tumor via TORS must be planned with curative intent

Patient must be willing to remain on corticosteroid therapy for 4 days postoperatively

Ability to understand and the willingness to sign a written informed consent document

Patients with known distant metastases or other malignancies

Patients with a history of allergy or adverse reaction to corticosteroids

Patients with a history of diabetes

Patients with fasting capillary blood glucose of > 140 on the day of surgery

Patients on chronic corticosteroids

Chronic alcohol abuse (> 6 alcoholic beverages daily)

Patients with a history of severe chronic pain on high dose narcotics (> 25 mg of oxycodone or equivalent daily) preceding diagnosis of cancer

Patients taking significant cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers, i. e. protease inhibitors (ritonavir, nelfinavir, etc), clarithromycin, ketoconazole, fluconazole, verapamil, diltiazem, carbamazepine, phenytoin, phenobarbital, Rifampin, efavirenz, nevirapine

Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study

Patients who will undergo complex head and neck surgery in addition to the TORS procedure requiring reconstruction with a free flap

Patients who have had any previous head and neck surgery that has affected swallowing, voice or speech or who have had previous radiation to the head or neck

Patients who have any confounding medical or neurological conditions that have the potential to affect cognition, speech or swallowing function; i. e. stroke, neurodegenerative disease, neuromuscular movement disorders, head injury, etcetera

Psychiatric illness/social situations that would limit compliance with study requirements

Excluded patients will be allowed to participate in the trial on an observational basis only

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials. gov identifier: NCT01748942

United States, Oregon

OHSU Knight Cancer Institute

Portland, Oregon, United States, 97239

Sponsors and Collaborators

OHSU Knight Cancer Institute

National Cancer Institute (NCI)

OHSU Knight Cancer Institute

OHSU Knight Cancer Institute

Other Study ID Numbers:

IRB00008071 NCI-2012-02780 CPC-12095-L CR00021919 IRB00008071 P30CA069533

Study First Received:

December 11, 2012

United States: Food and Drug Administration

Additional relevant MeSH terms:

Carcinoma Carcinoma, Squamous Cell Deglutition Disorders Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Pharyngeal Diseases Otorhinolaryngologic Diseases Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate

BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

ClinicalTrials. gov processed this record on September 19, 2016

Renacidin Irrigation Drug Information, Professional, Renicin

Renacidin Irrigation

Generic Name: Citric Acid, Glucono-delta-lactone, and Magnesium VA CLASSIFICATION Primary: GU900

Commonly used brand name(s): Renacidin Irrigation.

Note: For a listing of dosage forms and brand names by country availability, see Dosage Forms section(s).

Antiurolithic (apatite calculi; struvite calculi)—Citric Acid, Glucono-delta-lactone, and Magnesium;

Indications General considerations Citric acid, glucono-delta-lactone and magnesium carbonate solution will dissolve apatite calculi (calcium carbonate-phosphate compound) and struvite calculi (magnesium ammonium phosphates) but not calculi formed of calcium oxalate, uric acid, or cysteine .

Because many complications are associated with infusion of citric acid, glucono-delta-lactone, and magnesium carbonate solution into the renal pelvis, this treatment should be reserved for patients who are not candidates for surgical removal of calculi. Hospitalization is prolonged for days to weeks when chemolytic therapy is used in lieu of, or following, surgery .

Bladder calculi, apatite (treatment) or Bladder calculi, struvite (treatment)—Citric acid, glucono-delta-lactone, and magnesium carbonate combination is indicated for dissolution of bladder calculi as an alternative or adjunct to surgical procedures .

Catheter, urinary tract, patency maintenance—Citric acid, glucono-delta-lactone, and magnesium carbonate combination is used as an intermittent irrigation to prevent or minimize incrustations of indwelling urinary tract catheters .

Renal calculi, apatite (treatment) or Renal calculi, struvite (treatment)—Citric acid, glucono-delta-lactone, and magnesium carbonate combination is indicated for the dissolution of renal calculi composed of apatite or struvite in patients who are not candidates for surgical removal of the calculi . It may also be used as adjunctive therapy to dissolve residual apatite or struvite calculi and fragments after surgery or to achieve partial dissolution of renal calculi to facilitate surgical removal .

Magnesium in the irrigation solution exchanges for calcium in the apatite stone matrix, making the calculus soluble in the gluconocitrate irrigating solution and resulting in dissolution of the calculus. Struvite calculi are solubilized by the irrigation solution due to its acidic pH .

Precautions to Consider Carcinogenicity/Tumorigenicity/Mutagenicity

Long term studies to evaluate carcinogenicity of citric acid, glucono-delta-lactone, and magnesium carbonate solution have not been conducted . Mutagenicity studies have not been done . Pregnancy/Reproduction Pregnancy— Studies have not been done in humans. Studies have not been done in animals .

FDA Pregnancy Category C Breast-feeding

Magnesium is known to be distributed into human milk. It is not known whether citric acid, glucono-delta-lactone, and magnesium carbonate solution is distributed into human milk . However, problems in humans have not been documented. Pediatrics

Appropriate studies on the relationship of age to the effects of citric acid, glucono-delta-lactone, and magnesium carbonate solution have not been performed in the pediatric population.

No information is available on the relationship of age to the effects of citric acid, glucono-delta-lactone, and magnesium carbonate irrigation solution in geriatric patients. Drug interactions and/or related problems The following drug interactions and/or related problems have been selected on the basis of their potential clinical significance (possible mechanism in parentheses where appropriate)—not necessarily inclusive ( » = major clinical significance):

Magnesium-containing medications (May increase the likelihood of hypermagnesemia )

Laboratory value alterations The following have been selected on the basis of their potential clinical significance (possible effect in parentheses where appropriate)—not necessarily inclusive ( » = major clinical significance):

With physiology/laboratory test values Creatinine, serum Magnesium, serum Phosphate, serum (may become elevated )

Medical considerations/Contraindications The medical considerations/contraindications included have been selected on the basis of their potential clinical significance (reasons given in parentheses where appropriate)— not necessarily inclusive ( » = major clinical significance).

Except under special circumstances, this medication should not be used when the following medical problem exists: » Urinary tract infection (May lead to sepsis )

» Urinary tract extravasation Risk-benefit should be considered when the following medical problem exists » Impaired renal function (May increase likelihood of hypermagnesemia )

Patient monitoring The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition; » = major clinical significance):

» Creatinine, serum » Magnesium, serum Phosphate, serum (Measurements should be obtained every several days . Elevated serum magnesium and elevated creatinine are indications for halting irrigation until the parameters return to pre-irrigation levels . )

Deep tendon reflexes (Indicator of magnesium toxicity )

» Urine culture (Every three days or less and at first sign of fever )

Note: Severe hypermagnesemia has been reported with citric acid, glucono-delta-lactone, magnesium carbonate solution irrigation. Early signs and symptoms of hypermagnesemia include nausea, lethargy, confusion, and hypotension. Severe hypermagnesemia may result in hyporeflexia, dyspnea, apnea, coma, and cardiac arrest . Hyperphosphatemia and elevated serum creatinine also can occur with citric acid, glucono-delta-lactone, magnesium carbonate solution irrigation . Side effects of hyperphosphatemia include muscle cramps; numbness, tingling, pain, or weakness in hands or feet; and shortness of breath or troubled breathing.

The following side/adverse effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate)—not necessarily inclusive: Those indicating need for medical attention Incidence more frequent

urothelial ulceration/edema (blood in urine ; frequent urge to urinate; painful urination ) Incidence less frequent

Bladder irritability (blood in urine; frequent urge to urinate; painful urination, severe or continuing)

dysuria (difficult urination)

urinary tract infection (bladder pain; bloody or cloudy urine; difficult, burning, or painful urination; frequent urge to urinate; lower back or side pain )

Ileus ( abdominal pain; severe constipation ; severe vomiting)

septicemia (rapid breathing; chills; fever; abdominal pain; nausea; diarrhea)

thrombophlebitis ( bluish color changes in skin color; pain or tenderness; swelling of foot or leg)

Those indicating need for medical attention only if they continue or are bothersome Incidence more frequent

Incidence less frequent

hematuria, transient (blood in urine )

Overdose For specific information on the agents used in the management of hypermagnesemia due to the use of citric acid, glucono-delta-lactone, magnesium carbonate irrigation solution, see: • Calcium Supplements (Systemic) monograph.

For more information on the management of overdose or unintentional ingestion, contact a poison control center (see Poison Control Center Listing ). Clinical effects of overdose The following effects have been selected on the basis of their potential clinical significance (possible signs and symptoms in parentheses where appropriate)—not necessarily inclusive: Hypermagnesemia (Cardiac arrest ; chest pain; confusion; hyporeflexia; lightheadedness; nausea; shortness of breath or labored breathing; tiredness and weakness) Treatment of overdose

To decrease absorption: Discontinue irrigation with citric acid, glucono-delta-lactone, magnesium carbonate solution

Specific treatment: Administer calcium gluconate intravenously .

See Calcium Supplements (Systemic) for specific dosing guidelines for use of this product.

Monitoring: Serum magnesium

Supportive care: Administer fluids and diuretics in severe cases .

General Dosing Information

For topical dosing forms: Because of the high frequency of complications associated with irrigation of the renal pelvis, this procedure should be reserved for patients who are not candidates for surgical removal of calculi. In addition, chemolytic therapy prolongs hospital stay by days or weeks .

Care must be taken to maintain patency of the irrigation catheter .

Calculus fragments may obstruct the outflow catheter. Continued irrigation under these circumstances leads to increased intrapelvic pressure with risk of tissue damage or absorption of the irrigating solution. Catheter outflow blockage can be prevented by flushing the catheter with saline and repositioning the catheter. At the first sign of obstruction, irrigation should be discontinued and the system disconnected .

Intrapelvic pressure must be maintained at or below 25 centimeters (cm) of water. The preferred method of pressure control is the insertion of an open Y connection pop-off valve into the infusion line, allowing immediate decompression if pressure exceeds 25 cm of water. An alternative method is to direct or stop the flow of the irrigating solution to prevent increased pelvic pressure. This can be accomplished by placing a pinch clamp on the inflow line, which a nurse or the patient can use to stop the irrigation at the first sign of flank pain. However, caution must be taken when relying on cooperation of the patient. Patients may not be sufficiently alert to detect signs and symptoms of outflow obstruction

Patients with indwelling urethral or cystostomy catheters frequently have vesicoureteral reflux. A cystogram prior to initiation of irrigation with citric acid, glucono-delta-lactone, and magnesium carbonate solution is essential in such patients. If reflux is demonstrated, all precautions recommended for renal pelvis irritation must be taken .

For postoperative patients, irrigation should not be started before the fourth or fifth postoperative day .

Topical Dosage Forms CITRIC ACID, GLUCONO-DELTA-LACTONE, AND MAGNESIUM CARBONATE SOLUTION Usual Adult Dose Bladder calculi Topical, 30 mL instilled through a urinary catheter into the bladder and retained 30 to 60 minutes, 4 to 6 times per day .

Renal calculi Rate of flow, through a nephrostomy tube, equal to that tolerated in a test with sterile saline (between 60 mL/hr and 120 mL/hr), continuing until stones are no longer evident in nephrostomograms ; if stones fail to diminish in size after several days of adequate irrigation, the procedure should be discontinued .

Urinary tract catheter incrustation Topical, 30 mL instilled through the indwelling catheter and retained for 10 minutes, 3 times per day .

Usual Pediatric Dose Dosage has not been established. Usual Geriatric Dose See Usual adult dose. Strength(s) usually available U. S.—

Citric acid 6.602 grams per 100 mL, glucono-delta-lactone 0.198 gram per 100 mL, and magnesium carbonate 3.177 grams per 100 mL (Rx) [ Renacidin Irrigation (sterile, non-pyrogenic solution ) (benzoic acid USP)] Packaging and storage: Store below 40 °C (104 °F), preferably between 15 and 30 °C (59 and 86 °F). Protect from freezing and excessive heat.

Caution: Product should be inspected visually for particulate matter and discoloration prior to administration .

References

Product Information: Renacidin® Irrigation, citric acid, glucono-delta-lactone and magnesium carbonate solution. Guardian Laboratories, Hauppauge, NY (PI revised 10/1996) reviewed 5/2000.

Rejuven - Advanced Skincare, Wellbeing And Beauty Clinic, Rejuven

Advanced Skincare Wellbeing Beauty

You deserve to look and feel your best and here at Rejuven we will help you succeed.

Dedicated to enhancing the health and appearance of your skin through products that nurture, cutting edge treatment systems which truly deliver visible and corrective results, and all without the need for surgery or invasive procedures. Additionally, our wellbeing therapies will make you feel as good as you look.

Your professional therapist will deliver a tailored plan selecting the best treatments and products to keep you looking and feeling wonderful.

Featured Therapies

St Tropez is the U. K’s No. 1 Spray Tanning Brand.

3D-lipo is probably one of the most advanced treatments of its type in the field of targeted fat & cellulite reduction and skin tightening.

Home Of The Bika Open Source Lims Project - Bika Lims Collective, Bikalm

Home of the Bika Open Source LIMS project

Bika users say

Centro de Investigacion en Contaminacion Ambiental, Argentina

I acknowledge the great work they have done on this product. Working under the Open Source philosophy is very comfortable because it is a way to share and show work. I thank each of you for your knowledge, care and commitment. I congratulate you as a human and professional group - Marcos Cruz, IAEA fellow

ISO 9001 and 17025 certified bottling co-operative BBK

Quick, easy and hassle free. The Bika LIMS halved our paper work. The automated results publication, instrument interfaces and query functions are winners. Our analysts spend their time much more productively in the lab, far less on client queries. Highly efficient - Adel Stander, Lab Manager

Your donations keep Bika LIMS free

Do you like Bika LIMS? It is yours for the love of liberty. Help us sustain Bika LIMS. Please donate.

Cattle or code. And bug reports, feature requests and translations.

Metoclopramide - Brand Name List From, Piralen

Metoclopramide

See also.

Disclaimer: The indications, uses and warnings for individual medications outside the USA are determined by local regulatory bodies in each country or region. The Drugs. com website is intended primarily for audiences in the United States and its territories. Indications, uses and warnings on Drugs. com patient information leaflets are derived from FDA product labels and may differ in countries outside the USA. Every effort has been made to ensure that the information provided on this page is accurate, up-to-date and complete, but no guarantee is made to that effect. Drugs. com does not endorse drugs, diagnose patients or recommend specific therapies. The information on this page is not a substitute for the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that a drug or drug combination is safe, effective or appropriate for any given patient. Drugs. com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided here. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Always consult your doctor or healthcare specialist for medical advice.

Chemical formula: C14H22ClN3O2 Drugbank ID: DB01233 ATC code(s): A03FA01

Drugs. com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Support

About

Terms & Privacy

Connect

Subscribe to receive email notifications whenever new articles are published.

Drugs. com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Sep 2nd, 2016), Cerner Multum™ (updated Sep 5th, 2016), Wolters Kluwer™ (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

We comply with the HONcode standard for trustworthy health information - verify here

Copyright © 2000-2016 Drugs. com. All rights reserved.

Killing Vermetid Snails - General Discussion, Vermid

Like This

Unlike

mmelnick 06 May 2009

I have a huge population of vermetid snails. I didn't mind them at first, but they are now on every single rock in my tank. There are probably 5-10 per square inch in some areas and that nasty fishing line type stuff that they put out makes the tank look soo ugly. I've spent so much time and money on this tank and really don;t want it to be over run by these little buggers.

Is there anything I can do. II try snapping them off at the bast, but that only gets them about 20% of the time. I've tried using the super glue trick to trap them in thier tubes until they die but there are just way to many for that to work. Is there anything that will kill them without hurting my coral?

What about doing an iodine dip with each rock.

I have coral on almost every rock so it has to be a reef safe solution. But any thought would be greatly appreciated.

Like This

Unlike

nano-paul 06 May 2009

Like This

Unlike

knoxvegas 06 May 2009

I have them too. Probably close to the same amount. I also hate the stringy mess when I do WC's. You can TRY the superglue, but I've tried all kinds of attempts, including taking ea LR piece out and dremeling the suckers to death, but to no avail. You can't get them all, and they come back. What I have settled with is keeping the water column as clean as possible. It really does minimize the stringyness. They're still there in abundance but it's really much milder now and I only see it temporarily when doing WC's. Edited by knoxvegas, 06 May 2009 - 01:20 PM.

Like This

Unlike

reefdan 06 May 2009

he tried that already.

they really are a pain. i tried glue but with your infestation it'll get tiresome and expensive.

what i found most successful is taking out a rock a week (or day if you have the time) and just chiseling them off. smash the ones you can't chisel. i don't think there's an easy way out of this one.

Like This

Unlike

mmelnick 06 May 2009

I've tried using the super glue trick to trap them in their tubes until they die but there are just way to many for that to work.

But the dremmel idea is interesting. I know you sait it didn't work for you, but it might give temporary relief.

Like This

Unlike

RayWhisperer 06 May 2009

Take a heavy duty sewing needle. Stick it in each hole and prod it around a bit. Then snap the tube so you don't end up doing the same tubes over. It's time consuming, but it'll work.

Don't try to do it all at once. Just do a bit at a time, before each water change.

Like This

Unlike

mmelnick 06 May 2009

Take a heavy duty sewing needle. Stick it in each hole and prod it around a bit. Then snap the tube so you don't end up doing the same tubes over. It's time consuming, but it'll work.

Don't try to do it all at once. Just do a bit at a time, before each water change.

Hmm, thats a pretty good idea too. How many come back from that. I swear these guys are invincible.

Like This

Unlike

RayWhisperer 06 May 2009

Hmm, thats a pretty good idea too. How many come back from that. I swear these guys are invincible.

None will come back from it. What you are dealing with is a pest that is multiplying as fast as you are eradicating them. Over a few weeks you'll start to notice a difference.

Also, keep the water as clean as possible. They feed on almost anything they can catch from the water (assuming it's small enough). If they aren't getting enough food, they won't keep reproducing.

Like This

Unlike

John_A 06 May 2009

I had one on a rock and I took some aquamend putty and made a cone around it covering up the entire thing and just left I thought I would take it off but its starting to color so might just leave it

Like This

Unlike

Urchinhead 06 May 2009

What about a nice acid bath in say. Muriatic acid? Like what is used in swimming pools and can be found at pool supply places. Should kill just about everything plus leach any phosphates that are in the rock out.

Like This

Unlike

RayWhisperer 06 May 2009

What about a nice acid bath in say. Muriatic acid? Like what is used in swimming pools and can be found at pool supply places. Should kill just about everything plus leach any phosphates that are in the rock out.

Live rock is basically calcified. Ever see what acid does to that? Not to mention the wicked PH drop you'd get when you put the rock back in the tank.

Like This

Unlike

Psychosis 06 May 2009

I agree with most of the other posters here. Use some form of mechanical filtration method to help rid the water of free floating particles. No food, no babies. I like the simplicity of the needle method for the ones you have now.

Like This

Unlike

Urchinhead 06 May 2009

Live rock is basically calcified. Ever see what acid does to that? Not to mention the wicked PH drop you'd get when you put the rock back in the tank.

Awk! Good point! Forgot about that! Came across the idea for pulling PO4 off new rock going into a system and didn't bother to think it fully through. Thank you.

Like This

Unlike

mmelnick 06 May 2009

Awk! Good point! Forgot about that! Came across the idea for pulling PO4 off new rock going into a system and didn't bother to think it fully through. Thank you.

Yeah, plus the afore mentioned fact that I have coral on almost every rock. But I'll give the sewing needle thing a shot.

I would be hesitant to say that an atomic blast would kill them? But.

Does anyone think an iodine dip might kill them?

Like This

Unlike

DogfoodEnforcer 06 May 2009

i have a freaking monster vermetid in my tank on the base of one of my favourite corals. this thing's shell is a fortress.

im trying superglue tomorrow. if it doesnt work im trying the dremel!!

the opening to this thing's tube is nearly 1cm across!

Like This

Unlike

RayWhisperer 07 May 2009

I had one that was about 1/4" across at the opening and about 4 or 5" long. It was attached under a chalice frag, so I left it be. It was actually a very cool critter. They consume their own web with all the food on it.

Like This

Unlike

divecj5 08 May 2009

I wish you luck in getting rid of these bastages. I ended up taking down my 55 gallon when it got to the point where every single inch of live rock was covered in vermitids and they were starting to affect the corals.

I tried crushing them with a screwdriver, breaking them off, breaking their tubes with a needle to no avail. Hopefully you can get rid of them. they were the bane of my reef existence.

Like This

Unlike

apexstrafer 08 May 2009

Yeah those little guys are a pain, I ended up just getting rid of the rock that had them. Indestructible little pr*cks.

Like This

Unlike

lakshwadeep 08 May 2009

I had one that was about 1/4" across at the opening and about 4 or 5" long. It was attached under a chalice frag, so I left it be. It was actually a very cool critter. They consume their own web with all the food on it.

+1, but I had to remove it because it was on a christmas tree worm/feather duster rock. I don't think the larger individuals (mine was 1/4" in diameter) are the same species as the smaller, and more prolific, ones. One thing I did read was that hermit crabs are one predator of vermetids.

Like This

Unlike

Marteen 08 May 2009

+1, but I had to remove it because it was on a christmas tree worm/feather duster rock. I don't think the larger individuals (mine was 1/4" in diameter) are the same species as the smaller, and more prolific, ones. One thing I did read was that hermit crabs are one predator of vermetids.

Yeah I heard the same thing about hermits. I bet you could teach the hermits to associate the vermitids with food by breaking a couple open and letting them feast on their insides.

Primogyn Depot Disease Interactions, Primogyn

Primogyn Depot (estradiol) Disease Interactions

Estrogens (Includes Primogyn Depot) ↔ Abnormal Vaginal Bleeding

Severe Potential Hazard, High plausibility

Applies to: Abnormal Uterine Bleeding

The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Prolonged (> 1 year), unopposed estrogen use (i. e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma. The risk may be offset substantially by the addition of a progestin but may not be completely abolished. Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy. The same applies if recurrent or persistent bleeding develops during estrogen therapy.

References

Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986): 434-41

Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506

"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.

View all 28 references

Estrogens (Includes Primogyn Depot) ↔ Carcinomas (Estrogenic)

Severe Potential Hazard, High plausibility

Applies to: Neoplasia -- Estrogen Dependent

The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation. High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.

References

"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.

Schlesselman JJ "Oral contraceptives and breast cancer." Am J Obstet Gynecol 163 (1990): 1379-87

View all 57 references

Estrogens (Includes Primogyn Depot) ↔ Hypercalcemia In Breast Cancer

Severe Potential Hazard, Moderate plausibility

Applies to: Breast Cancer

When treated with an estrogen, patients with breast cancer and bone metastases may develop severe hypercalcemia, in which case the drug should be stopped and measures be taken to reduce serum calcium levels.

References

"Product Information. Climara (estradiol)." Berlex, Richmond, CA.

"Product Information. Ogen (estropipate topical)" Pharmacia and Upjohn, Kalamazoo, MI.

"Product Information. Estrace (estradiol)." Bristol-Myers Squibb, Princeton, NJ.

View all 11 references

Estrogens (Includes Primogyn Depot) ↔ Hypertension

Severe Potential Hazard, High plausibility

Applies to: Hypertension

The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension. Moreover, estrogens (and also progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk. Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity. These effects also increase with duration of therapy and patient age. Therapy with estrogens should be administered cautiously in patients with preexisting hypertension. Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary. In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.

References

"Product Information. Climara (estradiol)." Berlex, Richmond, CA.

"Product Information. Ogen (estropipate topical)" Pharmacia and Upjohn, Kalamazoo, MI.

Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21

View all 52 references

Estrogens (Includes Primogyn Depot) ↔ Thromboembolism/Cardiovascular

Severe Potential Hazard, High plausibility

Applies to: Thrombotic/Thromboembolic Disorder, Cerebral Vascular Disorder, History - Thrombotic/Thromboembolic Disorder, Ischemic Heart Disease

The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic or thromboembolic disorders. The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease. Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy. Although the clinical significance of these effects is unknown, epidemiological data suggest it may be dose-dependent. The risk is probably slight with the use of newer, low-dose oral contraceptives in the absence of known risk factors (e. g. smoker, particularly over the age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40). However, a much more significant risk has been reported with higher dosages, such as those used to treat prostate or metastatic breast cancer or those used in older formulations of birth control pills. Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits. Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of breast or prostatic malignancy.

References

Thorogood M, Mann J, Murphy M, Vessey M "Fatal stroke and use of oral contraceptives: findings from a case - control study." Am J Epidemiol 136 (1992): 35-45

Thorogood M "Risk of stroke in users of oral contraceptives." JAMA 281 (1999): 1255-6

Mishell DR "Contraception." N Engl J Med 320 (1989): 777-85

View all 60 references

Estrogens/Progestogens (Includes Primogyn Depot) ↔ Hepatic Neoplasms

Severe Potential Hazard, High plausibility

Applies to: Hepatic Tumor

The use of oral contraceptives is contraindicated in patients with liver tumors. An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen-progestin contraceptive use of at least 4 years and 8 years, respectively. Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver. Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.

References

Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989): 878-82

"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993): 635-7

View all 32 references

Estrogens (Includes Primogyn Depot) ↔ Gallbladder Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Gallbladder Disease

A two - to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy. The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins. Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.

References

"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.

"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.

"Product Information. Ortho Dienestrol Cream (dienestrol topical)" Ortho McNeil Pharmaceutical, Raritan, NJ.

View all 18 references

Estrogens (Includes Primogyn Depot) ↔ Hypercalcemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperparathyroidism, Renal Dysfunction, Hypercalcemia

Estrogens influence the metabolism of calcium and phosphorus. Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia. Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.

References

"Product Information. Estrace (estradiol)." Bristol-Myers Squibb, Princeton, NJ.

"Product Information. Climara (estradiol)." Berlex, Richmond, CA.

"Product Information. Estraderm (estradiol)." Ciba Pharmaceuticals, Summit, NJ.

View all 6 references

Estrogens (Includes Primogyn Depot) ↔ Hyperlipidemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used. Severe hyperlipidemia is known to sometimes cause pancreatitis. Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.

References

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998): 605-13

"Product Information. Estrace (estradiol)." Bristol-Myers Squibb, Princeton, NJ.

"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.

View all 24 references

Estrogens (Includes Primogyn Depot) ↔ Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease

Estrogens are primarily metabolized by the liver. Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance. Therapy with estrogens should be administered cautiously in patients with liver disease. In addition, clinicians should be aware that estrogen therapy may affect liver function tests. Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.

References

"Product Information. Ortho Dienestrol Cream (dienestrol topical)" Ortho McNeil Pharmaceutical, Raritan, NJ.

"Product Information. Ortho Novum 1/50 (mestranol-norethindrone)." Ortho Pharmaceutical Corporation, Raritan, NJ.

"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

View all 22 references

Estrogens/Progestogens (Includes Primogyn Depot) ↔ Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression

The use of oral contraceptives has been associated with an increased incidence of depression. It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression. Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.

References

"Product Information. Estinyl Tablets (ethinyl estradiol)" Schering Corporation, Kenilworth, NJ.

"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.

View all 22 references

Estrogens/Progestogens (Includes Primogyn Depot) ↔ Fluid Retention

Moderate Potential Hazard, Moderate plausibility

Applies to: Fluid Retention, Asthma, Renal Dysfunction, Seizures, Congestive Heart Failure, Migraine

Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.

References

"Product Information. Estrace (estradiol)." Bristol-Myers Squibb, Princeton, NJ.

"Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.

"Product Information. Demulen (ethinyl estradiol-ethynodiol)." Searle, Skokie, IL.

View all 25 references

Estrogens/Progestogens (Includes Primogyn Depot) ↔ Glucose Intolerance

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose. However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent. Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.

References

"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho Pharmaceutical Corporation, Raritan, NJ.

Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6

Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989): 316-28

View all 23 references

Estrogens/Progestogens (Includes Primogyn Depot) ↔ Thyroid Function Tests

Moderate Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease

When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests. Changes have mostly been reported with the use of combination oral contraceptives. Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay. Free T3 resin uptake may be decreased. On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.

References

"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical, Raritan, NJ.

"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn, Kalamazoo, MI.

"Product Information. Estratab (esterified estrogens)" Solvay Pharmaceuticals Inc, Marietta, GA.

View all 24 references

Primogyn Depot (estradiol) drug Interactions

There are 244 drug interactions with Primogyn Depot (estradiol)

Primogyn Depot (estradiol) alcohol/food Interactions

There are 3 alcohol/food interactions with Primogyn Depot (estradiol)

Bula Do Medicamento Nausedron 4mg-50ap 2ml, Nausedron

NAUSEDRON 4MG - 50ap 2ml

NAUSEDRON® Cloridrato de Ondansetrona Comprimidos Revestidos Solucao injetavel

FORMAS FARMACEUTICAS E APRESENTACOES: - NAUSEDRON Comprimidos Revestidos 8 mg:Embalagem com 10 comprimidos. Solucao Injetavel 4 mg: Embalagem com 1 e 50 ampolas de 2 ml Solucao Injetavel 8 mg: Embalagem com 1 e 50 ampolas de 4 ml USO PEDIATRICO OU ADULTO

COMPOSICAO - NAUSEDRON Comprimidos Revestidos: Cada comprimido contem: Cloridrato de Ondansetrona (DCB 1616.02- 1) equivalente a. 8 mg de Ondansetrona base. Excipiente q. s.p. 1 comp. (Excipiente: amido de milho, estearato de magnesio, lactose, polisorbato 80, celulose microcristalina, dioxido de silicio, glicolato sodico de amido, polietilenoglicol 6000, opadry beige). Solucao Injetavel: Cada ml contem: Cloridrato de Ondansetrona (DCB 1616.02- 1) equivalente a. 2 mg de Ondansetrona base. Veiculo esteril q. s.p. 1 ml (Veiculo: cloreto de sodio, citrato de sodio, acido citrico, agua para injetaveis).

INFORMACOES AO PACIENTE: - NAUSEDRON Nausedron® e indicado para controle de nauseas1 e vomitos2 provocados por quimioterapicos citotoxicos e pela radiacao, em pacientes com neoplasias. Caso o medicamento seja administrado em hospital, compete ao medico dar adequada informacao ao paciente ou seu responsavel em seu direito em aceitar ou recusar o tratamento, e apos alerta - lo para os beneficios e riscos esperados com o uso da medicacao ou a ausencia do tratamento, cuidar de obter seu consentimento (ou recusa) para sua aplicacao. A Ondansetrona permanece sob farmacovigilancia quanto a efeitos adversos e toxicidade a longo prazo, pois e um novo medicamento. Embora as pesquisas realizadas tenham indicado eficacia e seguranca quando corretamente indicado, podem ocorrer reacoes adversas imprevisiveis ainda nao descritas nem conhecidas. O prazo de validade do produto e de 36 meses, a partir da data de fabricacao impressa na embalagem externa, sendo que apos este prazo, o produto pode nao apresentar mais efeito terapeutico. Conservar o produto em temperatura ambiente, entre 15 e 30oC, protegido da luz. Os comprimidos devem ser tambem protegidos da umidade. TODO MEDICAMENTO DEVE SER MANTIDO FORA DO ALCANCE DAS CRIANCAS. NAO TOME REMEDIO SEM O CONHECIMENTO DE SEU MEDICO; PODE SER PERIGOSO PARA SUA SAUDE.

INFORMACOES TECNICAS - NAUSEDRON A Ondansetrona e um potente antagonista, altamente seletivo, dos receptores 5- HT3 da 5-hidroxitriptamina. Age como antiemetico e antinauseante, mas seu preciso mecanismo de acao no controle da nausea3 e vomito4 ainda nao e bem conhecido. Os agentes quimioterapicos e a radioterapia5 podem causar liberacao de 5-hidroxitriptamina no intestino delgado6, iniciando reflexo de vomito4 pela ativacao dos aferentes vagais nos receptores 5-HT3. A Ondansetrona inibe a excitacao da fibra vagal aferente induzida pela 5-hidroxitriptamina na mucosa7 intestinal bloqueando o inicio deste reflexo. A ativacao dos aferentes vagais pode tambem causar uma liberacao de 5- hidroxitriptamina na area postrema, localizada na parte inferior do quarto ventriculo, e isso pode tambem promover emese atraves de mecanismo central. Deste modo, o efeito da Ondansetrona no controle da nausea3 e do vomito4 seria devido ao antagonismo dos receptores 5-HT3, tanto no sistema nervoso periferico8 quanto no sistema nervoso9 central. Nos testes psicomotores, a Ondansetrona nao prejudicou a performance nem causou sedacao. O farmaco nao altera as concentracoes de prolactina10 serica.

INDICACOES: - NAUSEDRON Nausedron® esta indicado para o controle da nausea3 e do vomito4 induzidos por quimioterapia11 citotoxica e radioterapia5, em pacientes com neoplasias. Nausedron® esta tambem indicado para a prevencao e tratamento de nauseas1 e vomitos2 do pos - operatorio.

CONTRA-INDICACOES - NAUSEDRON O Cloridrato de Ondansetrona esta contra - indicado a pacientes que apresentem hipersensibilidade conhecida a droga.

ADVERTENCIAS - NAUSEDRON A Ondansetrona permanece sob farmacovigilancia quanto a efeitos adversos e toxicidade a longo prazo, pois e um novo medicamento. Embora as pesquisas realizadas tenham indicado eficacia e seguranca quando corretamente indicado, podem ocorrer reacoes adversas imprevisiveis, ainda nao descritas nem conhecidas. Gravidez12 e Lactacao13: Como a Ondansetrona atravessa a barreira placentaria e e encontrado no leite materno, o produto nao deve ser utilizado por mulheres gravidas ou em periodo de lactacao13, salvo se o beneficio esperado pelo paciente supere a possibilidade de risco para o feto ou lactente14. INTERACOES MEDICAMENTOSAS OU COM ALIMENTOS: Nao foram constatadas interacoes com outros medicamentos ou com alimentos.

REACOES ADVERSAS / COLATERAIS: - NAUSEDRON Foram relatados alguns casos de cefaleia15, sensacao de calor ou rubor na cabeca e no epigastrio e constipacao16 intestinal. Foram tambem observadas elevacoes nos niveis de transaminase, particularmente naqueles pacientes recebendo profilaxia para vomitos2 induzidos por cisplatina.

POSOLOGIA - NAUSEDRON Comprimidos (Adultos):_Quimioterapia11 altamente emetogenica (por exemplo, cisplatina): 1 comprimido contendo 8 mg de 8 em 8 horas durante 5 dias, apos o tratamento inicial com Ondansetrona injetavel. _Quimioterapia11 de menor potencial emetogenico (por exemplo com esquemas contendo ciclofosfamida, doxorrubicina ou carboplatina): 1 comprimido contendo 8 mg cerca de 1 a 2 horas antes da quimioterapia11, seguido de 1 comprimido de 8 em 8 horas durante 5 dias ou, apos o tratamento com Ondansetrona injetavel, 1 comprimido contendo 8 mg de 8 em 8 horas durante 5 dias. _Vomitos2 e nauseas1 induzidos por radioterapia5: 1 comprimido contendo 8 mg de 8 em 8 horas sendo a dose inicial 1 a 2 horas antes de iniciada a radioterapia5. A duracao do tratamento ira depender da extensao do curso da radioterapia5. Comprimidos (Criancas): A experiencia e atualmente limitada, mas a Ondansetrona foi efetiva e bem tolerada em criancas acima de 4 anos. Nestas, a dose e de 4 mg de 8 em 8 horas durante 5 dias, apos o tratamento inicial com Ondansetrona injetavel. Solucao Injetavel: A forma injetavel da Ondansetrona geralmente e utilizada em conjunto com a administracao oral, precedendo - a. A injecao17 intravenosa deve ser lenta, ou em infusao, durante 15 minutos, imediatamente antes da quimioterapia11. Nausea3 e Vomito4 do Pos - Operatorio: Adultos:- Para prevencao da nausea3 e vomito4 do pos-operatorio Nausedron® pode ser administrado oralmente na dose de 8 mg uma hora antes da anestesia18, seguida de outras duas doses de 8 mg em intervalos de 8 horas. Alternativamente uma dose unica de 4 mg pode ser administrada atraves da injecao17 intravenosa lenta na inducao da anestesia18. Para tratamento da nausea3 e vomito4 do pos-operatorio ja estabelecidos e recomendada uma dose unica de 4 mg administrada atraves de injecao17 intravenosa lenta. Criancas:- Ainda nao ha experiencia com o uso de Nausedron® na prevencao e tratamento da nausea3 e do vomito4 do pos-operatorio em criancas. Idosos:- Existem poucas experiencias com o uso de Nausedron® na prevencao e tratamento da nausea3 e do vomito4 do pos-operatorio em pessoas idosas. Pacientes com insuficiencia renal19:- Nao e requerida qualquer alteracao da via de administracao, dose diaria ou frequencia da dose. Pacientes com insuficiencia hepatica20:- O "clearance" da Ondansetrona e significativamente reduzido e a meia-vida plasmatica significativamente prolongada em pacientes com insuficiencia hepatica20 moderada ou severa. Nestes pacientes a dose total diaria nao deve exceder a 8 mg.

SUPERDOSAGEM: - NAUSEDRON Ate o momento e limitado o conhecimento sobre superdosagem com Ondansetrona. Contudo, dois pacientes que receberam doses de 84 mg e 145 mg por via intravenosa relataram somente minimos efeitos adversos e nao requereram terapia ativa. Nos casos de suspeita de superdosagem deve se adotar medidas sintomaticas e de suporte. Nausedron® injetavel nao deve ser administrado na mesma seringa21 ou infusao utilizadas com outra medicacao. Compatibilidade com fluidos intravenosos:- Nausedron® injetavel deve somente ser misturado com os liquidos de infusao recomendados. Segundo as boas praticas farmaceuticas, as solucoes intravenosas devem ser preparadas no momento da infusao. Contudo, demonstrou - se que Nausedron® injetavel e estavel durante 7 dias a temperatura abaixo de 25? C, sob luz fluorescente ou em refrigerador com os seguintes fluidos de infusao intravenosa:- Solucao intravenosa de cloreto de sodio BP 0,9% p/v; Solucao intravenosa de glicose22 BP 5% p/v; Solucao intravenosa de manitol BP 10% p/v; Solucao intravenosa de Ringer; Solucao intravenosa de cloreto de potassio 0,3% p/v e cloreto de sodio 0,9% p/v BP; Solucao intravenosa de cloreto de potassio 0,3% p/v e glicose22 5% p/v BP. Estudos de compatibilidade foram desenvolvidos em bolsas de infusao e equipo de administracao a base de cloreto de polivinila. Foi observado tambem que uma adequada estabilidade e conseguida com uso de bolsas de infusao de polietileno e com recipientes de vidro do tipo I. As diluicoes da Ondansetrona em cloreto de sodio 0,9% p/v ou em glicose22 5% p/v demonstraram ser estavel em seringas de polipropileno. Considera - se que a Ondansetrona injetavel, diluida com outros fluidos de infusao compativeis seja estavel em seringas de polipropileno. Nota:- As preparacoes devem ser efetuadas sob apropriadas condicoes assepticas caso sejam requeridos periodos maiores de estocagem. Compatibilidade com outras drogas:- Nausedron® injetavel pode ser administrado atraves de infusao intravenosa com 1 mg/ hora, por exemplo, atraves de um frasco de infusao ou bomba de infusao. As seguintes drogas podem ser administradas juntamente com Ondansetrona, nas concentracoes de 16 a 160 mcg/ml (por ex. 8 mg/500 ml, e 8 mg/50 ml respectivamente) atraves de equipo em Y. Cisplatina:- Concentracoes ate 0,48 mg/ ml (por ex. 240 mg em 500 ml) administrada durante 1 a 8 horas. 5- Fluoruracil:- Concentracoes ate 0,8 mg / ml (por ex. 2,4 g em 3 litros ou 400 mg em 500 ml), administrada a uma velocidade de pelo menos 20 ml/h (500 ml por 24 h.). A infusao de concentracoes de 5-fluoruracil podem causar precipitacao da Ondansetrona. A infusao de 5-fluoruracil pode conter ate 0,045% p/v de cloreto de magnesio em adicao a outros excipientes que se mostraram compativeis. Carboplatina:- Concentracoes na faixa de 0,18 mg / ml a 9,9 mg / ml (por ex. 90 mg em 500 ml a 990 mg em 100 ml) administradas durante 10 minutos a 1 hora. Etoposida:- Concentracoes na faixa de 0,14 mg / ml a 0,25 mg / ml (por ex. 72 mg em 500 ml a 250 mg em 1000 ml) administradas durante 30 minutos a 1 hora. Ceftazidima:- Doses na faixa de 250 mg a 2000 mg, reconstituidas com agua para injetaveis BP, como recomendado pelo fabricante (por ex. 2,5 ml para 250 mg e 10 ml para 2 g de ceftazidima), e administradas como injecao17 intravenosa em "bolo" durante aproximadamente 5 minutos. Ciclofosfamida:- Doses na faixa de 100 mg a 1 g, reconstituidas com agua para injetaveis BP, 5 ml por 100 mg de ciclofosfamida, como recomendado pelo fabricante, e administradas como injecao17 intravenosa em "bolo" durante aproximadamente 5 minutos. Doxorrubicina:- Doses na faixa de 10-100 mg reconstituidas com agua para injetaveis BP por 10 mg de doxorrubicina, como recomendado pelo fabricante, e administradas como injecao17 intravenosa em "bolo" durante aproximadamente 5 minutos. Dexametasona:- Podem ser administrados 20 mg de fosfato sodico de dexametasona como uma injecao17 intravenosa lenta durante 2-5 minutos ou atraves de equipo em Y de uma infusao liberando 8 ou 32 mg de Ondansetrona diluido em 50-100 ml de um liquido de infusao compativel durante aproximadamente 15 minutos. A compatibilidade entre o fosfato sodico de dexametasona e a Ondansetrona foi demonstrada com a administracao dessas drogas atraves do mesmo equipo, resultando em concentracoes na faixa de 32 mcg-2,5 mg/ml para fosfato sodico de dexametasona e 8 mcg-1 mg/ml para Ondansetrona.

VENDA SOB PRESCRICAO MEDICA

N. ? do lote, data de fabricacao e prazo de validade: vide rotulo/cartucho Reg. MS N. ? 1.0298.0124 Farm. Resp. Dr. Joaquim A. dos Reis CRF - SP N. ? 5061

SAC (Servico de Atendimento ao Cliente): 0800- 7011918

CRISTALIA - Produtos Quimicos Farmaceuticos Ltda. Rod. Itapira - Lindoia, km 14 Itapira - SP CNPJ N. ? 44.734.671/0001- 51 Industria Brasileira

REVISADO EM 24/09/01

NAUSEDRON 4MG-50ap 2ml - Laboratorio

Duphaston - Drug Review Dosage, Side Effects, Action, Buy Duphaston, Dufaston

Duphaston

Duphaston review

Duphaston is a brand name for the generic drug dydrogesterone. which is a synthetic hormone similar to progesterone. a naturally occurring sex hormone. Duphaston is used for several different menstrual disorders that occur due to a lack of progesterone in the body. Progesterone is necessary for the maintenance of a healthy endometrium. the lining of the uterus. required for pregnancy. The body produces progesterone at certain times of the month, making the uterus hospitable to a fertilized embryo. If no embryo appears, progesterone levels drop and the body sheds the lining of the uterus, resulting in a menstrual period. Taking Duphaston helps to regulate this process in women whose progesterone levels are low, so that they may be maintained at the level required for health and fertility.

Duphaston is used as a treatment for several different conditions related to progesterone production. If a woman experiences abdominal pain or bleeding during a pregnancy, or if she is pregnant but has a history of miscarriages, Duphaston can help sustain the necessary levels of hormones required to maintain a healthy pregnancy. It also relieves severe menstrual cramps or regulates menstrual periods if you have difficulty in these matters due to a progesterone deficiency. It helps treat endometriosis. an inflammation of the lining of the uterus, and helps regulate irregular menstrual cycles. It can stabilize the level of progesterone, thereby treating premenstrual syndrome. It also can help prevent the excessive growth of the endometrium that is a result of estrogen hormone replacement therapy. It is also used to treat infertility in women by re-establishing the levels of progesterone required for women to become pregnant.

Duphaston, like all medications, can cause some adverse reactions. Some of these may include headache. nausea. malaise, jaundice, abdominal pain, abnormal liver function, anemia. dizziness. skin reactions such as rash, itchiness, or hives. tenderness of the breasts. spotting or breakthrough bleeding between periods.

There are some people who should not use Duphaston. You should not take it if you have any blood clotting problems, or if you have had a heart attack or a stroke. You should not take it if you have liver disease or gall bladder problems, if you have ever had jaundice, if you have breast cancer or cancer of the genitals, or if you have any form of estrogen dependent cancer. You should not take Duphaston if you have had a form of liver cancer caused by oral contraceptives, if you have unusual vaginal bleeding, or if you have sickle cell anemia or other forms of abnormal red blood cells. Others who should not take Duphaston include those who have ever had herpes during pregnancy.

Duphaston is not known to cause harmful effects to a pregnancy, but you should make sure your doctor knows if you are pregnant before beginning Duphaston treatment. Small amounts of Duphaston may pass into breast milk, but there are no known negative effects on nursing babies. As with all medications, if you are plan to nurse a child while taking Duphaston, you should discuss it with your doctor.

Duphaston has the following structural formula:

• Molecular formula of duphaston is C21H28O2 • Chemical IUPAC Name is (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17- decahydrocyclopenta[a]phenanthren-3-one • Molecular weight is 312.4458 g/mol • Duphaston available. 10mg pills

Generic name: Dydrogesterone

Brand name(s): Diphaston, Dufaston, Duvaron, Gestatron, Gynorest, Prodel, Retrone, Terolut

Buy Brand Bi-Tildiem Online, Bi-Tildiem

Bi-Tildiem

Bi-Tildiem Product Description

When ordering Bi-Tildiem be sure to choose a reputable online pharmacy that you trust. PharmaPassport. com is the first choice when searching for safe and affordable Diltiazem. Be sure to visit our website and search for your medications at PharmaPassport. com.

You can trust PharmaPassport. com to provide you with the best price for Bi-Tildiem, since we price match all of our medications including Bi-Tildiem. We compare and match our prices to the lowest prices of other CIPA certified pharmacies. A prescription must be provided for Bi-Tildiem and all our prescription medication here at PharmaPassport. com. The customer must fax a copy of their prescription and following that the customer must mail the actual original prescription to PharmaPassport. com.

Diltiazem is the generic alternative to Bi-Tildiem.

As a reliable pharmacy we display our Canadian International Pharmacy Association (CIPA) seal on our website as well as the Pharmacy Checker seal. Since we are a CIPA certified pharmacy we follow the same standards as other reputable pharmacies such as your local pharmacy. PharmaPassport. com administers affordable Bi-Tildiem to American citizens. These customers can remain calm knowing that they are receiving Bi-Tildiem all their other prescription medications from a trustworthy pharmacy. We also provide our customers with the 3 part guarantee from buySAFE which includes lowest price guarantee, money back guarantee and identity theft protection.

Customers can order Bi-Tildiem online and many other quality medications from PharmaPassport. com at an affordable price. This online pharmacy allows you to purchase Bi-Tildiem 24 hours a day and 7 days a week. Once you order with us you can rest easy since we pride our self with reliable safe shipping. It takes approximately 2 to 4 weeks from the day you order it to arrive at your house. If you have any questions regarding medication or basic inquires about PharmaPassport. com you can contact us by mail, phone or internet. If you wish to speak to a representative be sure to call our toll free number 1-866-293-3904 from Monday to Friday from 6am to 6pm and Saturdays from 7am to 4pm.

Bi-Tildiem is available in dosages: Bi-Tildiem.

Professional Standards and Safety

PharmaPassport has a clean, spotless patient safety record that proves our commitment to customer safety. We:

Do not provide access to controlled, habit forming substances.

Do not provide access to prescription medications without a prescription from a physician.

Do contact the doctor's office to verify each prescription before it is filled.

Do have licensed Canadian physicians that reviews every customer's medical history to identify potential complications. A new prescription for the patients' preferred brand or generic medication will be written by our doctors to prevent the potential complications.

START SAVING ON CYMBALTA

Information provided on this website is for general purposes only. It is not intended to take the place of advice from your practitioner.

All trademarks and registered trademarks appearing on this website are the property of their respective owners and pharmapassport. com is not affiliated with them in any way.

Feel free to contact our Customer Care Specialists by: Calling Us Toll-Free: 1-866-293-3904 Faxing Us Toll-Free: 1-866-732-0306 Emailing Us: info@pharmapassport. com

Copyright © 2016 PharmaPassport. com. com. All Rights Reserved.

CALL US TOLL-FREE 1-866-293-3904

FAX US TOLL-FREE 1-866-732-0306

Maxitrol Eye Drops, Moxitral

MAXITROL EYE DROPS

Transcript

PMS ZWART a 100%

Package Leaflet - Information for the User

eye drops, suspension Dexamethasone, Neomycin sulphate, Polymyxin B sulphate Read all of this leaflet carefully before you start using this medicine • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

IN THIS LEAFLET 1. What MAXITROL is and what it is used for 2. Before you use MAXITROL 3. How to use MAXITROL

6. Further information

It is used for the short term treatment of inflammation of the eye, where administration of an antibiotic is also required to prevent an eye infection.

BEFORE YOU USE MAXITROL

Do not use MAXITROL. • If you have any type of infection of the eye that is not being treated. Use of steroids may make infections worse. • If you have a red eye that has not been seen by a doctor. • If you are allergic to neomycin or to any of the other ingredients listed in section 6. Ask your doctor for advice.

Take special care. • Do not inject or swallow this medicine. • Consult your doctor or pharmacist before using this medicine if you have a disorder causing a thinning of the eye tissues. • You should have your eye pressure checked regularly while using this medicine. This is especially important for children. • The risk of increase in eye pressure and / or cataract formation is higher in susceptible patients ( e. g. patients with diabetes ) using steroids. • Consult your doctor or pharmacist if your eye pain, redness, swelling, or irritation gets worse or persists. • Steroids applied to the eye may delay the healing of your eye wound. Topical NSAIDs ( Non-Steroidal Anti Inflammatory DrugsMedications ) are also known to slow or delay healing. Simultaneous use of topical NSAIDs and topical steroids may increase the potential for healing problems. • As with any antibiotic, use of MAXITROL for a long time may lead to other infections. If your symptoms get worse or suddenly return tell your doctor.

5. How to store MAXITROL

WHAT MAXITROL* IS AND WHAT IT IS USED FOR

MAXITROL contains a steroid, dexamethasone and two antibiotics, neomycin sulphate and polymyxin B sulphate.

4. Possible side effects

Pregnancy and breast-feeding MAXITROL is not recommended during pregnancy or breast-feeding. If you are pregnant or might get pregnant, or if you are breast-feeding a baby, talk to your doctor before you use MAXITROL.

Driving and using machines You may experience blurred vision after using MAXITROL. Do not drive or use any machines unless your vision is normal.

Using other medicines Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Taking MAXITROL with other medicines may increase the seriousness of the side effects. Tell your doctor if you are using topical NSAIDs. Simultaneous use of topical steroids and topical NSAIDs may increase healing problems in your eye.

Important information if you wear Contact Lenses Wearing contact lenses is not advisable during the treatment of an eye infection, as they may make your condition worse. If you do continue to wear your lenses, you must remove them before using MAXITROL and wait at least 15 minutes after use before putting your lenses back in. There is a preservative in MAXITROL ( benzalkonium chloride ) that can discolour soft contact lenses.

HOW TO USE MAXITROL

The usual dose The usual dose is 1 or 2 drops into the space between your eyelid and eye 6 times daily, or more frequently if required. Remove the loose collar from the cap when the bottle is first opened.

Always use MAXITROL exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. MAXITROL should not be used for a long period of time unless advised by your doctor.

PMS ZWART a 100% - 20%

HOW TO USE MAXITROL* ( continued )

Wash your hands before you start. Shake the bottle well. Twist off the bottle cap. Hold the bottle pointing down, between your thumb and fingers. 1 • Tilt your head back. • Pull down your lower eyelid with a finger, until there is a ‘pocket’ between the eyelid and your eye. The drop will go in here 2 ( picture 1 ).

• If a drop misses your eye, try again. • If you forget to take MAXITROL, do not worry, just take it as soon as possible. Do not take a double dose to make up. • If you use more MAXITROL than you should it can be washed out of your eye with warm water.

• Bring the bottle tip close to the eye. Do this in front of a mirror if it helps. • Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. It could infect the drops. • Gently press on the base of the bottle to release one drop at a time ( picture 2 ). • Do not squeeze the bottle, only a gentle press on the bottom is needed. • If you use drops in both eyes, repeat the steps for your other eye. Put the bottle cap firmly back on immediately after use.

• If you are using other eye drops, wait at least 5 minutes after putting in MAXITROL before using the other eye drops. Eye ointments should be administered last. If you have any further questions on the use of MAXITROL, ask your doctor or pharmacist.

POSSIBLE SIDE EFFECTS

Like all medicines, MAXITROL can cause side effects, although not everybody gets them. You may experience some or all of the following effects in your eyes : Uncommon ( affect 1 to 10 users in 1000 ) : eye surface inflammation, increased pressure in eye, blurred vision, sensitivity to light, change in pupil size, drooping of eye lid, eye pain, swelling or redness, eye irritation, itching or discomfort, abnormal eye sensation, increased tear production, Thinning of the surface of the eye has also been reported. It is not known how many users may have experienced this side effect.

You may also experience effects in other parts of your body : Hypersensitivity or general allergy to MAXITROL and headache have been reported. It is not known how many users may have experienced these side effects

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system ( see details below ). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom Yellow Card Scheme Website. www. mhra. gov. uk / yellowcard

HOW TO STORE MAXITROL

Keep out of the reach and sight of children. Do not refrigerate or store above 25 °C. Keep the bottle tightly closed. Keep away from direct sunlight. Do not use the drops after the expiry date ( marked ‘Exp’ ) on the bottle and the carton. The expiry date refers to the last day of that month.

• Stop using the bottle 4 weeks after first opening, to prevent infections. • Medicines should not be disposed of via waste water or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. • Do not pass this medicine on to others. It may harm them even if their symptoms are the same as yours.

What MAXITROL contains • The active substances are dexamethasone 1 mg / ml, neomycin sulphate 3500 IU / ml, polymyxin B sulphate 6000 IU / ml. • The other ingredients are sodium chloride, polysorbate 20, hypromellose, benzalkonium chloride, hydrochloric acid and / or sodium hydroxide ( to adjust pH ) and purified water.

Marketing authorisation holder : Alcon Laboratories ( UK ) Ltd. Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom. * a trademark of Novartis

What MAXITROL looks like and contents of the pack MAXITROL Eye Drops is a cloudy, white liquid supplied in a pack containing a 5 ml or 10 ml plastic bottle with a screw cap.

Manufacturer : SA Alcon-Couvreur NV Rijksweg 14, B-2870 Puurs, Belgium. This leaflet was last revised in July 2014.

© 2010, 2013, 2014 Novartis 07-2014

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Promodin, Promodin

Anxiety - Promodin (Brand name: phenergan)

Product Description Common use Phenergan is an antihistamine used to treat different types of allergy symptoms, including itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes. It works by decreasing the effects of histamine, a chemical the body releases in response to certain irritants. Also Phenegran is used as a sedative and sleep aid for all types of patients and prevent or control nausea and vomiting, treat motion sickness. You can use it with other medications, for pain after surgery also.

Dosage and direction Take it orally with or without food/milk. It is better take this medication with food if you want to avoid stomach upset. For treating allergy the recommended dose is 25 mg before sleeping. You can repeat the dose within two hours if necessary. For treating motion sickness the recommended dose is 25 mg twice daily. Note: this instruction presented here just for review. It's very necessary to consult your doctor before using. It will help you to get better results.

Precautions Do not give this drug to patients in coma. Do not use alcohol while taking Phenergan because it can extreme drowsiness. Avoid alcohol use. Phenergan may increase sensitivity to sunlight. Wear a sunscreen and protective clothing when you are exposed to the sun, it'll help you to avoid a heat stroke. Phenergan should not be used during pregnancy, becoming pregnancy or lactating without telling your doctor. Do not use before breast-feeding without doctor's advice.

Contraindications Phenergan is not allowed to children under 2 years of age. Phenergan is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. Also this drug is contraindicated for use in the treatment of lower respiratory tract symptoms including asthma.

Possible side effect They may include an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Also the most possible side effects include: twitching, or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs; tremor (uncontrolled shaking), drooling, trouble swallowing, problems with balance or walking; feeling restless, jittery, or agitated; high fever, stiff muscles, confusion, sweating, fast or uneven heartbeats, rapid breathing; feeling like you might pass out; seizure (convulsions); pale skin, easy bruising or bleeding, fever, sore throat, flu symptoms; decreased night vision, tunnel vision, watery eyes, increased sensitivity to light; hallucinations, agitation; nausea and stomach pain, skin rash, and jaundice (yellowing of the skin or eyes); urinating less than usual or not at all; joint pain or swelling with fever, swollen glands, muscle aches, chest pain, vomiting, unusual thoughts or behavior, and patchy skin color; or slow heart rate, weak pulse, fainting, slow breathing (breathing may stop).

Less serious include: dizziness, drowsiness, anxiety; blurred vision, dry mouth, stuffy nose; ringing in your ears; weight gain, swelling in your hands or feet; impotence, trouble having an orgasm; or constipation. If you experience one of them stop using Phenegran and tell your doctor as soon as possible. Also consult with your doctor about any side effect that seems unusual.

Drug interaction Phenergan interact with such drugs as: lithium (Eskalith, Lithobid); atropine (Atreza, Sal-Tropine), belladonna (Donnatal, and others), benztropine (Cogentin), dimenhydrinate (Dramamine), methscopolamine (Pamine), or scopolamine (Transderm-Scop); blood pressure medication such as guanadrel (Hylorel), guanethidine (Ismelin), propranolol (Inderal), and others; a blood thinner such as warfarin (Coumadin); bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva); bladder or urinary medications such as oxybutynin (Ditropan, Oxytrol), solifenacin (Vesicare), and others; an MAO inhibitor such as isocarboxazid (Marplan), tranylcypromine (Parnate), phenelzine (Nardil), selegiline (Eldepryl, Emsam); medicines to treat Parkinson's disease, restless leg syndrome, or pituitary gland tumor (prolactinoma); medicine to treat stomach ulcer or irritable bowel syndrome, such as dicyclomine (Bentyl), glycopyrrolate (Robinul), hyoscyamine (Anaspaz, Cystospaz, Levsin, and others), mepenzolate (Cantil), or propantheline (Pro-Banthine). Also note that interaction between two medications does not always mean that you must stop taking one of them. As usual it affects the the effect of drugs, so consult with your doctor about how it interactions are being managed or should be managed.

Missed dose If you forgot to take your dose in time, please do it as soon as you remember. But do not take if it is too late or almost time for your next dose. Do not take double or extra doses. Take your usually dose next day in the same regularly time.

Overdose Symptoms of Phenergan overdose may include: severe drowsiness, dizziness, dry mouth, large pupils, flushing, nausea, vomiting, shallow breathing, and fainting. If you experience one of them call your doctor immediately.

Storage Store at room temperature between 59-77 degrees F (15-25 degrees C) away from light and moisture, kids and pets. Do not use after expiration term.

Disclaimer We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Ripoff Report, Soderm

By consumers, for consumers.

Jill Jones Soderman, Psychotherapist, Mediator, Doctor Jill Jones Soderman, Dr. Jill Jones Soderman, the Healthymind, Jill Jones Solderman Jill Jones Soderman, The Foundation For The Child Victims Of T Fraudster Jill jones soderman is no doctor or even phd Nyack New York

AUTHOR: Jill - (USA)

SUBMITTED: Sunday, March 15, 2015

POSTED: Sunday, March 15, 2015

A note on trying to bully us: Having faced the brutal retaliation of the courts and related government agencies set out to defame, discredit, undermine the credibility of the FCVFC and staff, even questioning that the Foundation exists as a non-profit agency, we chose not to respond to the bullying tactics of liars and cowards.

We ignored blackmail threats expecting that the public would not give any credibility to an anonymous threat. Further, our position has been that anyone who gave credence to vicious, false statements were not clients with whom we would want to engage. Taking on the blood sport tactics of the courts does not square with dealing with clients who are naive or suspicious given the publishing and record of the Foundation's work.

The Foundation has concrete proof of the blackmail threats of individuals who were not clients of the Foundation. Our new resolve is to begin posting the names and facts surrounding this.

When the Foundation files complaints against authorities, complaints are filed with permission of the client and the name of the complainant filing a well documented statement of facts.

A note on threats:

Sometimes people who make threats follow through!

The Foundation and our staff will never give in to threats whether it be with anonymous fraudulent complaints on Rip Off Report ( Refer to the Blog of May 7th 2008 " New York & Thoughts on Jill Jones --Soderman posted below)

or an e mail address set up to collect false complaints through advertising on the internet written by Christine Sirgent the vindictive girl friend who was denied participation in meetings dealing with consultation on her boyfriend's high conflict custody case which had been ongoing for many years. The girl friend was not a party to the action, was not married to the litigant and could potentially testify against the litigant.

The litigant Joshua Clark never paid for an initial extensive document review begun 5/10/2014 and a five hour consultation at the office of an accountant 5/29/2014. The accountant, a member of the Foundation Board wouldhave been a critical part of the forensic team that would have worked on Mr. Clark's case for a minimal fee based on a minimal payment plan offered by Mr. Clark. Mr. Clark and Ms. Sirgent called our office repeatedly, spoke to staff of the Foundation. Out of sympathy for their pleas to meet with us we agreed to review documents and see what help could be offered based on an evaluation of the case. Mr. Clark never paid any part of fees charged by the Foundation though Mr. Clark and Ms. Sirgent placed in writing demands for money from the foundation with the threat that if we did not pay they would write negative comments about the Foundation.

Mr. Clark was dismissed as a client in part because his girl friend Ms. Sirgent proved to be completely out of control as to her demands and interference in the case. In reviewing documents on Mr, Clark's case it appeared that the Court in which his case was being litigated felt the same way. We have a full compliment of the documents, e mailed demands then threats sent by Ms. Sirgent, whom often wrote e mails as if she was in fact Mr. Clark, a fact easily discernible in comparison of writing styles of Ms. Sirgent and Mr. Clark.

While it had been our policy not to respond to cyber bullying, blackmail, various threats, the Foundation Board has currently ruled that any threats to any of our staff will be referred to the police and to our attorneys to avoid the ability of malevolent individuals to anonymously file complaints so they can avoid responsibility for their false allegations. In view of the fact that we have a complete set of documents from which we can prove our position, we have no problem responding to false allegations of those who may run but cannot hide!

Commentary on Rip Off Report

Actual words of Karl Hindle

Report Attachments:

AUTHOR: KARINA - ()

SUBMITTED: Wednesday, November 19, 2014

POSTED: Wednesday, November 19, 2014

Is everyone crazy who disagrees with the poster? Is everyone Jill herself or her cousin/niece/mother/aunt? What a rebuttal. People have different experiences than you, deal with it. What a horrible person you must be to not allow for a difference in opinion. My experience was far different from yours. Sorry if that makes you rage.

Respond to this report!

Are you an owner, employee or ex-employee with either negative or positive information about the company or individual, or can you provide "insider information" on this company?

AUTHOR: StarzzRipOff - ()

SUBMITTED: Thursday, July 10, 2014

POSTED: Thursday, July 10, 2014

If Soderman did not write these rebuttals herself, then whoever wrote them is delusional. Soderman is a fraud and a fake. She preys on vulnerable individuals to take any and all money they may have for a promise to FIX their corrupt family case. She is nothing more than a woman who thinks she talks a good talk, but the bottom line is she has dementia and repeats herself constantly and forgets important facts. She is a complete fraud and people need to stay away from her. She runs from state to state to escape the chaos she creates wherever she goes.

Respond to this report!

Are you an owner, employee or ex-employee with either negative or positive information about the company or individual, or can you provide "insider information" on this company?

AUTHOR: Serena - (United States of America)

SUBMITTED: Saturday, August 11, 2012

POSTED: Saturday, August 11, 2012

I have known Jill Jones Soderman for almost forty years and was present while she was a graduate student. After her PHD she persued further post graduate training in forensics. I was also present when Jill was developing the Foundation.

I am aware of people who attempted to extort money and services from her. As a client, I know that she does not deal with insurance companies in order to protect client confidenciality. Clients are billed for services rendered. In all the years I've known her and referred clients to her, I've never known her to engage in unethical or illegal action.

Both I and the clients I referred have benifited from her services.

Respond to this report!

Are you an owner, employee or ex-employee with either negative or positive information about the company or individual, or can you provide "insider information" on this company?

AUTHOR: Truth10101 - (United States of America)

SUBMITTED: Friday, September 30, 2011

POSTED: Friday, September 30, 2011

Jill helped me and my ex husband weather a very emotional divorce. Even my ex thinks she is amazing. Neither of us has ever had a better therapist. Fearlessly, she has gone after the courts in NJ and elsewhere, and these lies have popped up quite coincidentally. not. Also, she is the one who gets ripped off all the time by patients who do not pay her! I have personal knowledge of at least one of them! She is generous and very very smart. She couldn't rip off someone if she wanted to. it's just not in her makeup.

Respond to this report!

Are you an owner, employee or ex-employee with either negative or positive information about the company or individual, or can you provide "insider information" on this company?

Report & Rebuttal

Respond to this report!

Are you an owner, employee or ex-employee with either negative or positive information about the company or individual, or can you provide "insider information" on this company?

Are you also a victim of the same company or individual? Want Justice? File a Rip-off Report, help other consumers to be educated and don't let them get away with it!

Repair Your Reputation!

Got Reports filed against you? Resolve the issues and rebuild trust through our Corporate Advocacy Program.

Corporate Advocacy Program: The best way to manage and repair your business reputation. Hiding negative complaints is only a Band-Aid. Consumers want to see how businesses take care of business. All businesses will get complaints. How those businesses take care of those complaints is what separates good businesses from bad businesses.

Remove Reports? No! Better yet! Arbitrate to set the record straight!

Somnodent Oral Appliance Product Information, Somno

SomnoDent® Oral Appliance Information for Patients

An ideal treatment option: SomnoDent

A SomnoDent oral appliance is a premium, custom-fitted dental sleep appliance developed for the treatment of snoring and obstructive sleep apnea. It is an effective, comfortable, and durable alternative to CPAP therapy or corrective surgery. By simply wearing a SomnoDent while sleeping, your lower jaw (mandible) will be moved forward into a comfortable position, allowing relaxation of the tissues at the back of your throat and ensuring the base of your tongue does not collapse and block your airway, giving you a safe and soundless sleep. Most patients and practitioners prefer oral appliance therapy for its comfort, convenience and effectiveness.

Is a SomnoDent Oral Appliance Right for Me?

A growing number of men and women have discovered SomnoDent to be the perfect solution for ending snoring, treating sleep apnea and/or improving sleep quality. It is an ideal alternative treatment for patients who have been diagnosed with mild to moderate obstructive sleep apnea or for those who have severe OSA, yet are unable or unwilling to tolerate CPAP therapy and/or surgery.

SomnoDent Difference

Effective: 91% of patients reported improvement in sleep quality with SomnoDent?

Highest Quality: FDA 510K cleared. Class II Medical Devices, and manufactured at an ISO 13485 certified facility. Customized using the highest quality acrylic which does not discolor or attract odors.

Custom-fit: SomnoDent is manufactured using dental impressions of your teeth, ensuring and effortless, custom-fit unique to your mouth

Non-Restrictive in Movement: While wearing a SomnoDent, you will be able to fully open and close your mouth, yawn, drink, take oral medication and even speak clearly, making it ideal for the patient who may be claustrophobic.

Easily Adjustable: SomnoDent is unlimited in protrusive advancement, meaning that you can advance your lower jaw as forward as possible when wearing the device.

?AM / Respir Crit Care Med Vol 163. Pp 1457-1461, 2001

Highly Adaptable: If you have missing teeth, crowns, bridge work or wear a full upper denture, a SomnoDent can be adapted to fit your mouth structure.

Patient Compliance: 88% of patients reported regular use of their SomnoDent device?

Enduring Durability: A combination of premium materials and, for some models, inner cast framework, ensures that the SomnoDent oral device is one of the strongest appliances currently available, making it an ideal treatment option for all patients, especially teeth grinders (bruxers). 1 to 3 year warranty against manufacturing defects.

Clinically Proven: 15+ independent studies demonstrate the device’s significant clinical benefits

Combination Use: SomnoDent can conveniently be used as a companion to your CPAP for combination therapy, allowing simpler mask fitting, reduced CPAP pressure and a compact alternative for travelling.

Fluxilan, Fluxilan

Fluxilan

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Fluoxetine

Click for further information on drug naming conventions and International Nonproprietary Names .

Important Notice: The Drugs. com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Was this page helpful?

Enalapril Uses, Dosage, Side Effects, Renil

Enalapril

What is enalapril?

Enalapril is an ACE inhibitor. ACE stands for angiotensin converting enzyme.

Enalapril is used to treat high blood pressure (hypertension) in adults and children who are at least 1 month old.

Enalapril is also used to treat congestive heart failure in adults.

Enalapril is also used to treat a disorder of the ventricles (the lower chambers of the heart that allow blood to flow out of the heart). This disorder can decrease the heart's ability to pump blood to the body.

Important information

Do not use enalapril if you are pregnant. Stop using and tell your doctor right away if you become pregnant. Enalapril can cause injury or death to an unborn baby.

You should not use enalapril if you have ever had angioedema.

Enalapril can cause kidney problems. Call your doctor at once if you have swelling, rapid weight gain, little or no urinating, or if you feel short of breath.

If you have diabetes, do not use enalapril together with any medication that contains aliskiren (Amturnide, Tekturna, Tekamlo, Valturna).

Enalapril can affect your heart or your electrolyte levels. Call your doctor if you have chest pain, pounding heartbeats or fluttering in your chest, a slow heart rate or weak pulse, a tingly feeling, muscle weakness, or muscle tightness or contraction.

Before taking this medicine

You should not use enalapril if you are allergic to it, or if you have:

a history of angioedema; or

if you are allergic to any other ACE inhibitor, such as benazepril, captopril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, or trandolapril.

If you have diabetes, do not use enalapril together with any medication that contains aliskiren (Amturnide, Tekturna, Tekamlo, Valturna).

You may also need to avoid taking enalapril with aliskiren if you have kidney disease.

To make sure enalapril is safe for you, tell your doctor if you have:

kidney disease (or if you are on dialysis);

a history of blood clot or stroke (including "mini-stroke";

an electrolyte imbalance (such as high levels of potassium in your blood); or

heart disease or congestive heart failure (unless you are taking enalapril for this condition).

Do not use enalapril if you are pregnant. Stop using this medicine and tell your doctor right away if you become pregnant. Enalapril can cause injury or death to the unborn baby if you take the medicine during your second or third trimester. Use effective birth control while taking this medication.

Enalapril can pass into breast milk and may harm a nursing baby. You should not breast-feed while you are using this medicine.

How should I take enalapril?

Take enalapril exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not take this medicine in larger or smaller amounts or for longer than recommended.

You may take enalapril with or without food.

Shake the oral suspension (liquid) well just before you measure a dose. Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Your blood pressure will need to be checked often. Your kidney or liver function may also need to be tested.

You may have very low blood pressure while taking this medication. Call your doctor if you are sick with vomiting or diarrhea, or if you are sweating more than usual.

If you need surgery, tell the surgeon ahead of time that you are using enalapril. You may need to stop using the medicine for a short time.

If you are being treated for high blood pressure, keep using this medicine even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medicine for the rest of your life.

Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.

Store the liquid medicine in the refrigerator, do not freeze. Throw away any enalapril liquid not used within 60 days.

Enalapril dosing information

Usual Adult Dose for Hypertension:

Initial dose (oral tablets or solution): 5 mg orally once a day Maintenance dose (oral tablets or solution): 10 to 40 mg orally per day as a single dose or in 2 divided doses Maximum dose: 40 mg orally daily as a single dose or in 2 divided doses

In combination with diuretics: Initial dose: 2.5 mg orally once a day If feasible, the diuretic should be discontinued 2 to 3 days prior to initiation of therapy with enalapril. If required, diuretic therapy may be gradually resumed.

Parenteral: 1.25 to 5 mg IV over a 5 minute period every 6 hours

Comments: - Clinical response is usually seen within 15 minutes after IV administration. - If required, diuretic therapy may be gradually resumed.

Usual Adult Dose for Congestive Heart Failure:

Initial dose: 2.5 mg orally once a day Maintenance dose: 2.5 to 20 mg daily in 2 divided doses Maximum dose: 40 mg orally per day in 2 divided doses

Comments: - Treatment is usually combined with diuretics and digitalis. - Doses should be titrated upward, as tolerated, over a period of a few days or weeks.

Usual Adult Dose for Left Ventricular Dysfunction:

Initial dose: 2.5 mg orally twice a day Maintenance dose: 20 mg orally per day in 2 divided doses

Comments: - After the initial dose, the patient should be observed for at least 2 hours and until blood pressure has stabilized for at least an additional hour. - If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension.

Usual Pediatric Dose for Hypertension:

Oral tablets or solution: Children 1 month to 17 years: Initial dose: 0.08 mg/kg/day (up to 5 mg) in 1 to 2 divided doses. Adjust dosage based on patient response. Maximum dose: Doses greater than 0.58 mg/kg (40 mg) have not been evaluated in pediatric patients.

Comment: - Not recommended in neonates and in pediatric patients with glomerular filtration rate less than 30 mL/min, as no data are available.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking enalapril?

Avoid drinking alcohol. It can further lower your blood pressure and may increase some of the side effects of enalapril.

Do not use salt substitutes or potassium supplements while taking enalapril, unless your doctor has told you to.

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.

Enalapril side effects

Get emergency medical help if you have any signs of an allergic reaction to enalapril . hives; severe stomach pain; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

a light-headed feeling, like you might pass out;

pounding heartbeats or fluttering in your chest;

high potassium - slow heart rate, weak pulse, muscle weakness, tingly feeling;

low white blood cell counts - sudden weakness or ill feeling, fever, chills, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing; or

signs of a kidney problem - little or no urinating; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath.

Common enalapril side effects may include:

dizziness, tired feeling;

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect enalapril?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with enalapril, especially:

a diuretic or "water pill";

gold injections to treat arthritis;

medicine to prevent organ transplant rejection - everolimus, sirolimus, temsirolimus; or

NSAIDs (nonsteroidal anti-inflammatory drugs) - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others.

This list is not complete. Other drugs may interact with enalapril, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

More about enalapril

Consumer resources

Professional resources

Related treatment guides

Where can I get more information?

Your pharmacist can provide more information about enalapril.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use enalapril only for the indication prescribed.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2016 Cerner Multum, Inc. Version: 10.02. Revision Date: 2016-02-12, 3:59:07 PM.

Was this page helpful?

Amarwin, Amarwin

Product Description Common use Amaryl is an oral blood sugar-lowering drug which belongs to the class of sulfonylureas. Active substance is Glimepiride. It is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. The mechanism of its action is to stimulate the secretion and release of insulin from beta cells of the pancreas (pancreatic effect). Amaryl is used to treat non-insulin depending diabetes (type 2) as monotherapy or in combination with insulin (or metformin).

Dosage and direction

The best dose is determined by a physician on a basis of regular measurements of blood sugar content.

Be careful your sugar does not fall too low due to stress, skipping a meal, exercising too long, or drinking alcohol. Know signs of hypoglycemia and keep a source of sugar at hand. If your sugar level is too high you may feel very thirsty or hungry. You may also urinate more than usual. Take this medication exactly as prescribed as it is a part of a complicated program consisting of diet, medication, and exercise routines. Tell your doctor if you are pregnant or plan to become pregnant, have adrenal or pituitary gland problems before taking this medication.

Contraindication Amaryl is contraindicated in patients with history of diabetic ketoacidosis, diabetic coma and prekoma, insulin-dependent diabetes (type 1), severe renal dysfunction, severe hepatic impairment, individual hypersensitivity to Amaryl, other members of sulfonylurea class and sulfonamides.

Possible side effect If you have any signs of allergic reaction to this medication such as hives, swelling of face and throat, rash or other major symptoms (severe skin rash, itching, redness, pale skin, easy bruising or bleeding, numbness, dark urine, clay-colored stools, abdominal pain, fever, nausea)seek for immediate medical help.

Drug interaction Diuretics like hydrochlorothiazide (Hydrodiuril, Ezide, Hydro-Par, Microzide, furosemide (Lasix)), corticosteroids such as prednisone and methylprednisolone (Medrol), phenytoin (Dilantin), niacin, and sympathomimetics such as pseudoephedrine (Sudafed) are able to increase blood sugar and diminish effect of Amaryl. Propranolol (Inderal) and atenolol (Tenormin) belong to beta-blockers and also are able to affect blood levels and decrease activity of Amaryl.

Missed dose Take the missed dose as soon as you remember about it. If it is almost time of your next dose just skip it and return to your regular schedule.

Overdose Immediate medical attention is needed in case you took too much medicine. Possible side effects include: extreme weakness, confusion, blurred vision, stomach pain, trouble speaking, tremors, sweating, seizure, and coma.

Storage Store at room temperature in a tight container and keep away from sunlight, moisture, kids and pets.

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information on the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Pelmec - Arts & Crafts - Route Du Bois-Des-Freres 36, Le Lignon, Geneve, Switzerland - Phone Number

Pelmec

Aww, your browser has JavaScript turned off!

Example: There are a few times in life when a meal is so expertly crafted and planned that it is nothing short of genius. Last night, I had one of those meals - the Mahi Mahi.

The dish was excellently prepared. Grilled, juicy, and fresh without a hint of fishiness. A glaze of tangerine sauce brought a hint of tart sweetness. The fish was placed on a mound of sweet plantain rice. The combination of the fish and rice alone was to die for!

However, as only expert chefs can achieve, additional garnishes provided even bolder, beautiful tastes. Pickled onions topping the fish made for an even finer taste experience, while green beans hidden under the fish added freshness and completed each bite

Download the app

Get those thumbs ready to leave a review using the Yelp Mobile App!

Pelmec

More Business Info

Is this your business? Claim your business page to respond to reviews and customer messages.

Etodolac Uses, Dosage, Side Effects, Etopan

Etodolac

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body.

Etodolac may also be used for purposes not listed in this medication guide.

Important information

Etodolac can increase your risk of fatal heart attack or stroke, especially if you use it long term or take high doses, or if you have heart disease. Do not use this medicine just before or after heart bypass surgery (coronary artery bypass graft, or CABG).

Etodolac may also cause stomach or intestinal bleeding, which can be fatal. These conditions can occur without warning while you are using etodolac, especially in older adults.

Call your doctor at once if you have symptoms of bleeding in your stomach or intestines. This includes black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.

Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Many medicines available over the counter contain aspirin or other medicines similar to etodolac (such as ibuprofen, ketoprofen, or naproxen). If you take certain products together you may accidentally take too much of this type of medication. Read the label of any other medicine you are using to see if it contains aspirin, ibuprofen, ketoprofen, or naproxen. Do not drink alcohol while taking this medicine. Alcohol can increase the risk of stomach bleeding caused by etodolac. Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). This medicine can make your skin more sensitive to sunlight and sunburn may result.

Before taking this medicine

Etodolac can increase your risk of fatal heart attack or stroke, especially if you use it long term or take high doses, or if you have heart disease. Even people without heart disease or risk factors could have a stroke or heart attack while taking this medicine.

Do not use this medicine just before or after heart bypass surgery (coronary artery bypass graft, or CABG).

Etodolac may also cause stomach or intestinal bleeding, which can be fatal. These conditions can occur without warning while you are using this medicine, especially in older adults.

You should not use etodolac if you are allergic to it, or if you have ever had an asthma attack or severe allergic reaction after taking aspirin or an NSAID.

To make sure etodolac is safe for you, tell your doctor if you have:

heart disease, high blood pressure, high cholesterol, diabetes, or if you smoke;

a history of heart attack, stroke, or blood clot;

a history of stomach ulcers or bleeding;

liver or kidney disease; or

Taking etodolac during the last 3 months of pregnancy may harm the unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using etodolac.

Etodolac can pass into breast milk and may harm a nursing baby. You should not breast-feed while using this medicine.

The etodolac regular tablet is not approved for use by anyone younger than 18 years old. The extended-release form of etodolac is not approved for use by anyone younger than 6 years old.

How should I take etodolac?

Take etodolac exactly as it was prescribed for you. Follow all directions on your prescription label. Do not take this medicine in larger amounts or for longer than recommended. Use the lowest dose that is effective in treating your condition.

Do not crush, chew, or break an extended-release tablet. Swallow it whole.

It may take up to 2 weeks before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve.

If you use this medicine long-term, you may need frequent medical tests.

This medicine can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using etodolac.

Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.

Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking etodolac?

Avoid drinking alcohol. It may increase your risk of stomach bleeding.

Avoid taking aspirin or other NSAIDs while you are taking etodolac.

Ask a doctor or pharmacist before using any cold, allergy, or pain medication. Many medicines available over the counter contain aspirin or other medicines similar to etodolac. Taking certain products together can cause you to get too much of this type of medication. Check the label to see if a medicine contains aspirin, ibuprofen, ketoprofen, or naproxen.

Etodolac side effects

Get emergency medical help if you have signs of an allergic reaction to etodolac: sneezing, runny or stuffy nose; wheezing or trouble breathing; hives; swelling of your face, lips, tongue, or throat.

Get emergency medical help if you have signs of a heart attack or stroke: chest pain spreading to your jaw or shoulder, sudden numbness or weakness on one side of the body, slurred speech, feeling short of breath.

Stop using etodolac and call your doctor at once if you have:

changes in your vision;

the first sign of any skin rash, no matter how mild;

shortness of breath (even with mild exertion);

swelling or rapid weight gain;

signs of stomach bleeding - bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;

liver problems - nausea, upper stomach pain, itching, tired feeling, flu-like symptoms, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);

kidney problems - little or no urinating, painful or difficult urination, swelling in your feet or ankles, feeling tired or short of breath;

low red blood cells (anemia) - pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating; or

severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common etodolac side effects may include:

nausea, vomiting, stomach pain, indigestion;

diarrhea, constipation, gas;

sore throat, runny nose, flu symptoms;

itching, rash; or

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Etodolac dosing information

Usual Adult Dose for Osteoarthritis:

Capsules or tablets: 300 mg orally 2 to 3 times a day or 400 mg orally twice a day or 500 mg orally twice a day. Total daily dose should not exceed 1200 mg.

Extended-release tablets: 400 to 1200 mg orally, given once daily.

Usual Adult Dose for Rheumatoid Arthritis:

Capsules or tablets: 300 mg orally 2 to 3 times a day or 400 mg orally twice a day or 500 mg orally twice a day. Total daily dose should not exceed 1200 mg.

Extended-release tablets: 400 to 1200 mg orally, given once daily.

Usual Adult Dose for Pain:

Capsules or tablets: 200 to 400 mg orally every 6 to 8 hours. Total daily dose should not exceed 1200 mg.

Usual Pediatric Dose for Juvenile Rheumatoid Arthritis:

Extended-release tablets: 6 to 16 years: dose based on weight, given orally once daily

For 20 to 30 kg, dose is 400 mg For 31 to 45 kg, dose is 600 mg For 46 to 60 kg, dose is 800 mg For greater than 60 kg, dose is 1000 mg

What other drugs will affect etodolac?

Ask your doctor before using etodolac if you take an antidepressant such as citalopram, escitalopram, fluoxetine (Prozac), fluvoxamine, paroxetine, sertraline (Zoloft), trazodone, or vilazodone. Taking any of these medicines with an NSAID may cause you to bruise or bleed easily.

Tell your doctor about all your current medicines and any you start or stop using, especially:

a blood thinner (warfarin, Coumadin, Jantoven);

heart or blood pressure medication, including a diuretic or "water pill"; or

steroid medicine (prednisone and others).

This list is not complete. Other drugs may interact with etodolac, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

More about etodolac

Consumer resources

Professional resources

Related treatment guides

Where can I get more information?

Your pharmacist can provide more information about etodolac.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use etodolac only for the indication prescribed.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2016 Cerner Multum, Inc. Version: 10.01. Revision Date: 2015-09-08, 9:51:23 AM.

Drug Status

Dipyridamole - Blood Pressure, Docdipyri

Dipyridamole is used for evaluating coronary artery disease in patients who cannot exercise adequately before thallium imaging (cardiac blood flow scan). Dipyridamole is a coronary vasodilator. It works by increasing blood flow to the heart, which mimics an exercise test. It is followed by the thallium test.

Use Dipyridamole as directed by your doctor.

Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.

Take Dipyridamole with a full glass (8 ounces) of water.

Dipyridamole is often taken together with other medications to prevent blood clots. To best treat your condition, use all of your medications as directed by your doctor.

To be sure this medication is not causing harmful effects, your doctor may need to check your progress on a regular basis. Do not miss any scheduled visits to your doctor.

If you miss a dose of Dipyridamole, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.

Ask your health care provider any questions you may have about how to use Dipyridamole.

Store Dipyridamole at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Do not freeze. Keep Dipyridamole out of the reach of children and away from pets.

Do NOT use Dipyridamole if:

you are allergic to any ingredient in Dipyridamole.

Some medical conditions may interact with Dipyridamole. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have asthma; chest pain (angina); heart disease; heart block; or abnormal, rapid, slow, or irregular heartbeat

if you have severe muscle weakness.

Some medicines may interact with Dipyridamole. Tell your health care provider if you are taking any other medicines, especially any of the following:

Theophyllines (eg, aminophylline) because they may decrease Dipyridamole's effectiveness

Adenosine because the risk of its side effects, including low blood pressure and irregular heartbeat, may be increased by Dipyridamole

Anticholinesterases (eg, pyridostigmine) because their effectiveness may be decreased by Dipyridamole.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dipyridamole may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Dipyridamole may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Dipyridamole with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Avoid food or drink that has caffeine (eg, coffee, tea, cocoa, cola, chocolate) before you use Dipyridamole.

Dipyridamole should not be used in children; safety and effectiveness in children have not been confirmed.

Pregnancy and breast-feeding: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dipyridamole while you are pregnant. Dipyridamole is found in breast milk. Do not breastfeed while taking Dipyridamole.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Dizziness; fatigue; flushing; headache; nausea.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; fast, irregular, or slow heartbeat; one-sided weakness; seizures; slurred speech.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

Dipyridamole is used for evaluating coronary artery disease in patients who cannot exercise adequately before thallium imaging (cardiac blood flow scan). Dipyridamole is a coronary vasodilator. It works by increasing blood flow to the heart, which mimics an exercise test. It is followed by the thallium test.

Use Dipyridamole as directed by your doctor.

Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.

Take Dipyridamole with a full glass (8 ounces) of water.

Dipyridamole is often taken together with other medications to prevent blood clots. To best treat your condition, use all of your medications as directed by your doctor.

To be sure this medication is not causing harmful effects, your doctor may need to check your progress on a regular basis. Do not miss any scheduled visits to your doctor.

If you miss a dose of Dipyridamole, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.

Ask your health care provider any questions you may have about how to use Dipyridamole.

Store Dipyridamole at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Do not freeze. Keep Dipyridamole out of the reach of children and away from pets.

Do NOT use Dipyridamole if:

you are allergic to any ingredient in Dipyridamole.

Some medical conditions may interact with Dipyridamole. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have asthma; chest pain (angina); heart disease; heart block; or abnormal, rapid, slow, or irregular heartbeat

if you have severe muscle weakness.

Some medicines may interact with Dipyridamole. Tell your health care provider if you are taking any other medicines, especially any of the following:

Theophyllines (eg, aminophylline) because they may decrease Dipyridamole's effectiveness

Adenosine because the risk of its side effects, including low blood pressure and irregular heartbeat, may be increased by Dipyridamole

Anticholinesterases (eg, pyridostigmine) because their effectiveness may be decreased by Dipyridamole.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dipyridamole may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Dipyridamole may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Dipyridamole with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Avoid food or drink that has caffeine (eg, coffee, tea, cocoa, cola, chocolate) before you use Dipyridamole.

Dipyridamole should not be used in children; safety and effectiveness in children have not been confirmed.

Pregnancy and breast-feeding: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dipyridamole while you are pregnant. Dipyridamole is found in breast milk. Do not breastfeed while taking Dipyridamole.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Dizziness; fatigue; flushing; headache; nausea.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; fast, irregular, or slow heartbeat; one-sided weakness; seizures; slurred speech.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

Mobic Oral Uses, Side Effects, Interactions, Pictures, Warnings - Dosing, Probitor

Mobic

GENERIC NAME(S): MELOXICAM

Warnings

Nonsteroidal anti-inflammatory drugs (including meloxicam ) may rarely increase the risk of a heart attack or stroke. The risk may be greater if you have heart disease or increased risk for heart disease (for example, due to smoking. family history of heart disease. or conditions such as high blood pressure or diabetes ), or with longer use. This drug should not be taken right before or after heart bypass surgery (CABG).

Also, this drug may rarely cause serious (rarely fatal) bleeding from the stomach or intestines. This effect can occur without warning symptoms at any time while taking this drug. Older adults may be at higher risk for this effect. (See also Precautions and Drug Interactions sections.)

Stop taking meloxicam and get medical help right away if you notice any of the following rare but serious side effects: bloody or black/tarry stools, persistent stomach /abdominal pain. vomit that looks like coffee grounds, chest/jaw/left arm pain, shortness of breath, unusual sweating. weakness on one side of the body, sudden vision changes, slurred speech.

Talk with your doctor or pharmacist about the risks and benefits of treatment with this medication .

Uses

Meloxicam is used to treat arthritis. It reduces pain, swelling, and stiffness of the joints. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID).

If you are treating a chronic condition such as arthritis. ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This medication may also be used to treat gout attacks.

How to use Mobic

Read the Medication Guide provided by your pharmacist before you start taking meloxicam and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth as directed by your doctor, usually once daily. Drink a full glass of water (8 ounces/240 milliliters) with it unless your doctor tells you otherwise. Do not lie down for at least 10 minutes after taking this drug.

If you are taking the liquid form of this medication, shake the bottle gently before each dose. Carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.

If stomach upset occurs while taking this medication, take it with food, milk, or an antacid. The dosage is based on your medical condition and response to treatment. The lowest effective dosage should always be used, and only for the prescribed length of time. Do not take more of this medication than prescribed because higher doses increase the chance of stomach ulcers/bleeding.

The capsule form of meloxicam delivers different amounts of medication than the tablet and solution forms. Do not switch between the capsule and other forms of meloxicam without your doctor's permission and directions.

It may take up to two weeks before you get the full benefit of this drug. Use this medication regularly to get the most benefit from it. Remember to use it at the same time each day.

Tell your doctor if your condition worsens.

Side Effects

See also Warning section.

Stomach upset, nausea. dizziness. or diarrhea may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

This medication may raise your blood pressure. Check your blood pressure regularly and tell your doctor if the results are high.

Tell your doctor right away if you have any serious side effects, including: easy bruising/bleeding, persistent/severe headache. mental/mood changes, sudden/unexplained weight gain. swelling of the hands/feet, signs of kidney problems (such as change in the amount of urine), unexplained stiff neck. unusual tiredness.

This drug may rarely cause serious (possibly fatal) liver disease. Get medical help right away if you have any symptoms of liver damage, including: dark urine, persistent nausea/vomiting /loss of appetite, stomach/abdominal pain, yellowing eyes /skin .

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction. including: rash. itching /swelling (especially of the face/tongue /throat), severe dizziness, trouble breathing .

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www. fda. gov/medwatch.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before taking meloxicam, tell your doctor or pharmacist if you are allergic to it; or to aspirin or other NSAIDs (such as ibuprofen. naproxen. celecoxib ); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: asthma (including a history of worsening breathing after taking aspirin or other NSAIDs), liver disease, stomach/intestine/esophagus problems (such as bleeding, ulcers, recurring heartburn), heart disease (such as history of heart attack), high blood pressure, stroke, blood disorders (such as anemia, bleeding/clotting problems), growths in the nose (nasal polyps).

Kidney problems can sometimes occur with the use of NSAID medications, including meloxicam. Problems are more likely to occur if you are dehydrated, have heart failure or kidney disease, are an older adult, or if you take certain medications (see also Drug Interactions section). Drink plenty of fluids as directed by your doctor to prevent dehydration and tell your doctor right away if you have any unusual change in the amount of urine.

This medication may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely.

This medication may cause stomach bleeding. Daily use of alcohol and tobacco, especially when combined with this medication, may increase your risk for stomach bleeding. Limit alcohol and smoking. Consult your doctor or pharmacist for more information.

This medication may make you more sensitive to the sun. Avoid prolonged sun exposure, tanning booths, and sunlamps. Use a sunscreen and wear protective clothing when outdoors.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Older adults may be more sensitive to the side effects of this drug, especially stomach bleeding and kidney problems.

Before using this medication, women of childbearing age should talk with their doctor(s) about the benefits and risks (such as miscarriage, trouble getting pregnant). Tell your doctor if you are pregnant or if you plan to become pregnant. During pregnancy, this medication should be used only when clearly needed. It is not recommended for use during the first and last trimesters of pregnancy due to possible harm to the unborn baby and interference with normal labor/delivery.

It is unknown if this medication passes into breast milk. However, similar drugs pass into breast milk and are unlikely to harm a nursing infant. Consult your doctor before breast-feeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Some products that may interact with this drug include: aliskiren, ACE inhibitors (such as captopril, lisinopril), angiotensin II receptor blockers (such as losartan, valsartan), cidofovir, lithium, methotrexate (high-dose treatment), "water pills" (diuretics such as furosemide).

This medication may increase the risk of bleeding when taken with other drugs that also may cause bleeding. Examples include anti-platelet drugs such as clopidogrel, "blood thinners" such as dabigatran/enoxaparin/warfarin, among others.

If you are using the liquid form of meloxicam, tell your doctor if you are also using sodium polystyrene sulfonate.

Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (aspirin, NSAIDs such as celecoxib, ibuprofen, or ketorolac). These drugs are similar to meloxicam and may increase your risk of side effects if taken together. However, if your doctor has directed you to take low-dose aspirin to prevent heart attack or stroke (usually at dosages of 81-325 milligrams a day), you should continue taking the aspirin unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.

Overdose

If overdose is suspected, contact a poison control center or emergency room right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: slow/shallow breathing, extreme drowsiness, severe stomach pain, vomit that looks like coffee grounds.

Notes

Do not share this medication with others.

Laboratory and/or medical tests (such as blood counts, blood pressure, kidney/liver function tests) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

Non-drug treatment for arthritis that is approved by your doctor (such as weight loss if needed, strengthening and conditioning exercises) may help improve your flexibility, range of motion, and joint function. Consult your doctor for more information.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Storage

Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Information last revised May 2016. Copyright(c) 2016 First Databank, Inc.

Images

Buy Pausene Estradiol Online Without Prescriptions, Pausene

Estrace is used for treating conditions due to menopause (eg, hot flashes; vaginal itching, burning, or dryness), treating vulval or vaginal atrophy, and preventing osteoporosis (brittle bones). It is also used for estrogen replacement therapy after failure of the ovaries and to relieve the symptoms of breast cancer. Estrace is used for treating advanced prostate cancer.

Use Estrace as directed by your doctor.

Take Estrace by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

Grapefruit and grapefruit juice may increase the risk of Estrace's side effects. Talk to your doctor before including grapefruit or grapefruit juice in your diet while you are taking Estrace.

If you miss a dose of Estrace, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Estrace.

Store Estrace at room temperature, 59 to 86 degrees F (15 to 30 degrees C), in a tight, light-resistant container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Estrace out of the reach of children and away from pets.

Active Ingredient: Estradiol.

Do NOT use Estrace if:

you are allergic to any ingredient in Estrace

you are pregnant or suspect you may be pregnant, have recently given birth or are breast-feeding, or have vaginal bleeding of abnormal or unknown cause

you have known or suspected breast cancer (unless directed by your doctor) or you have cancers that are estrogen-dependent

you have blood clots, vein inflammation, or liver disease

you have had a recent stroke or heart attack.

Contact your doctor or health care provider right away if any of these apply to you.

Some medical conditions may interact with Estrace. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are planning to become pregnant

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a family history of breast cancer, or you have breast lumps or disease, or an abnormal mammogram

if you have yellowing of the whites of the eyes or skin during pregnancy or with past estrogen use, or high blood pressure during pregnancy (toxemia)

if you have a vaginal infection or womb problems (eg, uterine fibroids/endometriosis, abnormal vaginal bleeding, other uterine problems)

if you have abnormal calcium levels in the blood, asthma, cancer, certain blood disorder (porphyria), cholesterol or lipid problems, depression, diabetes, epilepsy, excessive weight gain, gallbladder disease, heart disease or other heart problems, high blood pressure, kidney or liver disease, low thyroid hormone levels, lupus, migraine headaches, pancreas disease, seizures, or yellowing of the skin or eyes

if you smoke or will be having surgery.

Some medicines may interact with Estrace. Tell your health care provider if you are taking any other medicines, especially any of the following:

Blood thinners (eg, warfarin), corticosteroids (eg, prednisone), succinylcholine, or tacrine because their actions and the risk of their side effects may be increased by Estrace

Blood thinners (eg, warfarin) because their effectiveness may be decreased by Estrace

Barbiturates (eg, phenobarbital), hydantoins (eg, phenytoin), or rifampin because they may decrease Estrace's effectiveness.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Estrace may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

Estrace may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Estrace with caution. Do not drive or perform other possible unsafe tasks until you know how you react to it.

Limit alcoholic beverages while you are taking Estrace.

Estrace may cause dark skin patches on your face (melasma). Exposure to the sun may make these patches darker and you may need to avoid prolonged sun exposure and sunlamps. Consult your doctor regarding the use of sunscreens and protective clothing.

Estrace may increase the risk of blood clots. The risk may be greater if you smoke (especially in women older than 35 years of age).

Contact your doctor if vaginal bleeding of unknown cause occurs. This could be a sign of a serious condition requiring immediate medical attention.

Contact your doctor if vaginal discomfort occurs or if you suspect you have developed an infection while taking Estrace.

Follow your doctor's instructions for examining your breasts and report any lumps immediately.

Additional monitoring of your dose or condition may be necessary if you are presently taking an azole antifungal (eg, itraconazole), carbamazepine, a macrolide antibiotic (eg, erythromycin), ritonavir, cimetidine, or St. John's wort.

If you wear contact lenses and you develop problems with them, contact your doctor.

If you will be having surgery or will be confined to a chair or bed for a long period of time (eg, a long plane flight), notify your doctor beforehand. Special precautions may need to be taken in these circumstances while you are taking Estrace.

Nonprescription therapy to help prevent bone loss includes a weight-bearing exercise plan, as well as adequate daily calcium and vitamin D intake. Consult your doctor or pharmacist for more details.

Some of these products may contain the dye tartrazine (FD&C Yellow No. 5), which can cause allergic reactions in certain patients. Consult your doctor or pharmacist. If you previously had allergic reactions to the dye tartrazine, contact your doctor or pharmacist to determine if the product you are taking contains the dye tartrazine.

Estrace may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Estrace.

Diabetes patients - Estrace may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

Lab tests, including physical exams and blood pressure, may be performed while you use Estrace. You should have breast and pelvic exams, and a Pap test at least once a year. You should also have periodic mammograms as determined by your doctor. Be sure to keep all doctor and lab appointments.

Estrace should not be used in children; safety and effectiveness in children have not been confirmed.

Pregnancy and breast-feeding: Do not use Estrace if you are pregnant. Avoid becoming pregnant while you are taking it. If you think you may be pregnant, contact your doctor right away. Estrace may be found in breast milk. If you are or will be breast-feeding while you use Estrace, check with your doctor. Discuss any possible risks to your baby.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Breast pain or tenderness; headache; hair loss; mild nausea or vomiting; spotting or breakthrough bleeding; stomach cramps or bloating.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); back pain;breast discharge or lump in the breast; calf or leg pain or swelling; chest pain; coughing up blood; dark urine; depression; dizziness; fainting; fever; memory problems; mental or mood changes; muscle pain; one-sided weakness; painful or difficult urination; persistent or severe breast pain or tenderness; persistent or severe headache, nausea, or vomiting; severe stomach pain or swelling; slurred speech; sudden shortness of breath; sunburn-like rash; swelling of hands, legs, or feet; unusual vaginal bleeding, discharge, itching, or odor; vision changes; vomiting; weakness or numbness of an arm or leg; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider.

All medicines may cause side effects, but many people have no, or minor, side effects.

Check with your doctor if any of these most common side effects persist or become bothersome:

Breast pain or tenderness; headache; hair loss; mild nausea or vomiting; spotting or breakthrough bleeding; stomach cramps or bloating.

Seek medical attention right away if any of these severe side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); back pain;breast discharge or lump in the breast; calf or leg pain or swelling; chest pain; coughing up blood; dark urine; depression; dizziness; fainting; fever; memory problems; mental or mood changes; muscle pain; one-sided weakness; painful or difficult urination; persistent or severe breast pain or tenderness; persistent or severe headache, nausea, or vomiting; severe stomach pain or swelling; slurred speech; sudden shortness of breath; sunburn-like rash; swelling of hands, legs, or feet; unusual vaginal bleeding, discharge, itching, or odor; vision changes; vomiting; weakness or numbness of an arm or leg; yellowing of the skin or eyes.

Vitamist - Osteo-Calmag, Osteocal

Osteo-CalMag

Osteo-CalMag gives your body the benefits of no less than thirteen herbs from around the globe; each used throughout history in the treatment of countless health problems.

Osteo-CalMag is designed as an herbal supplement with the addition of calcium, magnesium and Vitamin D. The purpose of this product is to provide a balanced herbal extract as a dietary supplement that will aid in the maintenance and absorption of calcium within the body. Each of the herbs included in the product has been used as a source of calcium or as an aid to the absorption of calcium from other dietary sources. The product contains extracts of 13 different herbs, ranging from alfalfa to valerian.

One daily adult dose of VitaMist Osteo-CalMag product provides both calcium and magnesium from each of 13 different herbs. In addition, we have added soluble and readily available calcium and magnesium in the forms of calcium ascorbate and magnesium gluconate. These two ingredients help to maintain a steady supply of calcium and magnesium electrolytes.

Osteo-CalMag contains vitamin D, which is a vitamin considered vital for the absorption of calcium from all sources. Vitamin D is a highly recommended vitamin, especially for the elderly, and those who have limited exposure to the sun.

Osteo-CalMag should be viewed as a maintenance product, and be used in conjunction with a good diet including calcium rich foods. Since your body does not produce calcium, you may be able to get it through other sources, including:

Dairy products, such as cheese, milk and yogurt

Dark green leafy vegetables, such as broccoli and kale

Fish with edible soft bones, such as sardines and canned salmon

Calcium-fortified foods and beverages, such as soy products, cereal and fruit juices

Even if you eat a healthy, balanced diet, you may find it difficult to get enough calcium if you:

Follow a vegan diet

Have lactose intolerance and limit dairy products

Consume large amounts of protein or sodium, which can cause your body to excrete calcium

Have osteoporosis

Are receiving long-term treatment with corticosteroids

Have certain bowel or digestive diseases that decrease your ability to absorb calcium, such as inflammatory bowel disease or celiac disease

If your concern is that you might not be getting enough calcium in your diet, you should check with your doctor. He or she will be able to tell you if calcium supplementation is right for you.

It is important to note that mega dosing with calcium will have little to no additional benefit, as levels of calcium above those recommended by the FDA (1,000 mg per day) are unlikely to be absorbed by your body. In fact, taking calcium in excess of 2,000 mg per day may actually do you more harm than good.

Shake gently.

Spray directly into mouth, 8 sprays per day.

Suggested use - 2 sprays, 4 times a day.

Supplement Facts

Topamax Oral Uses, Side Effects, Interactions, Pictures, Warnings - Dosing, Pamax

Topamax

Uses

Topiramate is used alone or with other medications to prevent and control seizures (epilepsy ). This medication is also used to prevent migraine headaches and decrease how often you get them. Topiramate will not treat a migraine headache once it occurs. If you get a migraine headache. treat it as directed by your doctor (such as by taking pain medication, lying down in a dark room).

Topiramate is known as an anticonvulsant or antiepileptic drug.

How to use Topamax

Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking topiramate and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with or without food as directed by your doctor, usually twice daily. Swallow the tablets whole since breaking them may leave a bitter taste. To prevent kidney stones from forming, drink plenty of liquids while taking this medication unless your doctor instructs you otherwise.

Dosage is based on your medical condition and response to treatment. For children, the dosage is also based on weight. Your doctor will gradually increase your dose to reduce your risk of side effects. For some conditions, you may start treatment with topiramate once daily at bedtime and slowly increase your dose to twice a day. It may take several weeks or months to reach the best dose for you and to get the full benefit from this medication.

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same times each day. Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Your dose may need to be gradually decreased.

Tell your doctor if your condition persists or if it worsens.

Side Effects

Tiredness, drowsiness, dizziness. loss of coordination, tingling of the hands/feet, loss of appetite, bad taste in your mouth. diarrhea. and weight loss may occur. Mental problems such as confusion, slowed thinking, trouble concentrating or paying attention, nervousness, memory problems, or speech/language problems may also occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if any of these unlikely but serious side effects occur: signs of kidney stones (such as severe back/side/abdominal/groin pain, fever, chills, painful/frequent urination. bloody/pink urine).

A small number of people who take anticonvulsants for any condition (such as seizures, bipolar disorder. pain) may experience depression. suicidal thoughts/attempts, or other mental/mood problems. Tell your doctor right away if you or your family/caregiver notice any unusual/sudden changes in your mood, thoughts, or behavior including signs of depression. suicidal thoughts/attempts, thoughts about harming yourself.

Tell your doctor right away if any of these rare but serious side effects occur: rapid breathing, fast/slow/irregular heartbeat. bone pain, broken bones, loss of consciousness, unusual bleeding/bruising.

Rarely, topiramate may cause a very serious eye problem, generally within 1 month of starting treatment. If untreated, this eye problem can lead to permanent blindness. Therefore, get medical help right away if any of these side effects occur: sudden vision changes (such as decreased vision. blurred vision ), eye pain /redness.

This medication can rarely cause a serious metabolic problem (high amount of ammonia in the blood ), especially if you are also taking valproic acid. Tell your doctor right away if you experience sudden/unexplained tiredness, vomiting. or mental changes (such as decreased alertness).

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction. including: rash. itching /swelling (especially of the face/tongue /throat), severe dizziness, trouble breathing .

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www. fda. gov/medwatch.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before taking topiramate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: a certain eye problem (narrow angle glaucoma ), kidney problems (such as kidney stones), liver problems, mental/mood problems (such as depression. thoughts of suicide), lung /breathing problems, a certain metabolic imbalance (metabolic acidosis ), long-term diarrhea, a diet high in fat and low in carbohydrates (ketogenic diet ), brittle bones (osteoporosis ).

This drug may make you dizzy or drowsy or impair your judgment. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Avoid alcoholic beverages.

This medication may make you sweat less, making you more likely to get heat stroke. Avoid doing things that may cause you to overheat, such as hard work or exercise in hot weather, or using hot tubs. When the weather is hot, drink a lot of fluids and dress lightly. If you overheat, quickly look for a place to cool down and rest. Get medical help right away if you have a fever that does not go away, mental/mood changes, headache, or dizziness.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Children may be more sensitive to the side effects of this drug, especially weakened bones, slowed growth rate, and decreased sweating. Consult your doctor or pharmacist for more details.

Older adults may be more sensitive to the side effects of this drug, especially dizziness. Dizziness can increase the risk of falling.

During pregnancy, this medication should be used only when clearly needed. It may harm an unborn baby. Discuss the use of reliable forms of birth control with your doctor (see also Drug Interactions section). If you are planning pregnancy, become pregnant, or think you may be pregnant, immediately talk to your doctor about the benefits and risks of using this medication during pregnancy. If you are taking this drug to treat seizures, note that untreated seizures are a serious condition that can harm both a pregnant woman and her unborn baby, so do not stop taking this medication unless directed by your doctor.

This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.

Interactions

See also Side Effects section.

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

This medication may decrease the effectiveness of hormonal birth control products (such as pills, patch, ring). This effect can result in pregnancy. Ask your doctor or pharmacist for details. Discuss whether you should use additional reliable birth control methods while using this medication. Also tell your doctor if you have any new spotting or breakthrough bleeding, because these may be signs that your birth control is not working well.

Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), muscle relaxants, and narcotic pain relievers (such as codeine).

Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.

Overdose

If overdose is suspected, contact a poison control center or emergency room right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness, loss of consciousness.

Notes

Do not share this medication with others.

Laboratory and/or medical tests (such as eye exams, bicarbonate blood level) should be performed to monitor your progress and check for side effects.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is within 6 hours of your next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up. If you miss more than one dose, call your doctor for advice.

Storage

Store in a tightly closed container at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).

Information last revised October 2015. Copyright(c) 2015 First Databank, Inc.

Images

Nodia, Nodia

is one of the leading suppliers in Benelux of diagnostic kits and biochemicals with applications in Haemostasis, Fibrinolysis, and Endotoxin testing

The core of our activities is formed by the innovative productline from Hyphen BioMed (France) and ACC, Associates of Cape Cod (US).

We focus on reagents and biochemicals for application in Pharmaceutical Quality Control, Clinical Diagnosis, and Research.

DOAC monitoring

Thrombodynamics

New NaPTT reagent

Endotoxin Testing

Chromogenic Factor VIII:c

Noida

Understand Edit

Just across the Yamuna River from Delhi, this is Uttar Pradesh's most modern city and a popular location for businesses looking to escape Delhi's congestion and steep rents. NOIDA boasts of the best roads in NCR, with excellent street lighting and cat-eyes which ensures maximum visibility during nights. It makes the whole driving experience a pleasure. Now with NOIDA Metro i. e. an extension to Delhi Metro, you can reach from Delhi to NOIDA in no time. If you want to know more have a look at North India News

Get in Edit

The easiest way to go to Noida by public transport is to take the Delhi Metro or the Buses of DTC (Delhi Transport Corporaion), which has numerous stops around the city.

The DND Flyway toll bridge (Rs.25) connects Noida to Delhi and is a pleasure to drive. Note that if you're driving a black-plated commercial vehicle — in particular, a rented car — you're not allowed to use the bridge unless you've already paid the Uttar Pradesh road tax of Rs.240/day (there are no facilities for paying it here).

Get around Edit

Noida is spottily connected by buses and rickshaws. The buses are chiefly from Delhi and ply here on a

By taxi Edit

A taxi or hired car (usually with driver) is required to see many of the far-flung sites within and around Noida.

Most Noida taxis are reliable run Indica Vista or Dzire in distinctive yellow plate back in side. The hired family car of choice is usually a Toyota Innova or Swift Dzire . Most trips around the city should be Rs 200-500, while a trip to the airport would be higher, depending on starting location. An eight-hour charter should cost around Rs 1,500, and a tip is expected if the driver is helpful. The prices would also depends upon the vehicle size too.

You can also book chauffeur driven cab for full day and half day travel from Clear car Rental this service is useful for the traveler who wants to travel within city or for local sightseeing within the city limits.

Best Tourist Vehicle Are: Indica. Indigo, Swift Desire, Toyota Etios, Toyota Corolla and Innova.

See Edit

A scenic relief from Delhi, Noida is low on traffic and pollution (by Indian standards) and is dotted with parks and statues, none of them particularly noteworthy though. The city has done very well to keep up the green cover and the plantation of trees is done from time to time.

Noida Film City - A hub for films and television in India - Founded by Sandeep Marwah of Marwah Studios

Stupa 18 Gallery ( Art Gallery ), K - 64, Sector 18 ( Close to Sector 18 Metro station ), ? +98 11028157. [1]. W-M 11AM-8PM. An art gallery, where you can see and buy art pieces by various new as well as established talented artists. Open to public, this gallery has interesting exhibitions every month. Art lovers would love to be there. INR 2000 onwards.  edit

Do Edit

Buy Edit

Noida is filled with malls and shopping centers.

CenterStage Mall . Sector 18 ( Atta Market, behind the Radisson ).

Great India Place [4]. next to Sector-18, Noida. BIG CINEMAS cineplex, slick (and pricy) Spoon food court on the 3rd floor, Big Bazaar department store, somewhat forlorn amusement part outside.

Spice Mall . Features a multiplex with 8 screens.

Sab Shopping Mall .

Shopprix Mall . Sector 61. Small, somewhat scruffy shopping mall with a good selection of restaurants and a small Subhiksha supermarket, but little else to recommend it.

Shipra Mall . This is in Gaziabad but just touching sec-62 Noida you can visit this Mall too.

Apart from that Noida is filled with old style Indian markets like Atta, Indira Market, Choura, Khoda, Chellara, Harola, Naya Bans etc.

Serviced Apartment Noida ( Bella Vista ), Sector-93, 56 Noida. ? 9811634552. [5]. Stay in a fully furnished apartment or a motel, guesthouse accommodation. Price range from INR 1,500/- per night to INR 5,000/- per night.  edit

Learn Edit

Ishaan Music College, affiliated to Indira Kala Sangeet University, Khairagarh, Chhattisgarh, The only centre in Noida with recognised courses and recognition by Noida Authority. Learn Indian & Western Dances, vocal and instrumental music. Drawing and painting. Best teachers of Noida. P-19, Sector-12, Noida. +91 9015034746

Eat Edit

Budget Edit

Haldiram . The best quality food with great hygeine @ PVR Spice Mall and also a new Haldiram is open @ Noida electronic city entrance on the left side.

Taste of India . Centerstage Mall Level 1, Sector 18. Food court style operation with eight stations dishing out a full range of Indian food, all of it vegetarian. Large set meals from Rs.100.

Brahmaputra Market . This place is flooded with food vendors in the evening, and good veg & non-veg out there, Sector 29.

Laxmi Coffee House . This is good old South Indian food joint. Cheap and tasty. Brahmaputra Market, Sector 29.

Sagar Ratna . This is good solid South Indian food. Many locations in Noida, at Gulmohar Shopping Complex at Sec 15, Sector 18 and at Shopprix Mall.

Reena Restaurant . This offers very good south indian food at reasonable rates.

Mid-range Edit

i'lario ITALIAN coffee bar & bakery . G-34, Sector-18, Phone: (0120)421-5666. URL: [6]. Italian Restaurant, Coffee Bar & Bakery,

Bercos Gardens Chinese Joint, Baraat Ghar . Sector 12

Samarkand Offers Indian Mughlai and Chinese, Ganga Shopping Complex, Sector 29.

Fortune Platters . Joint offering Indian, Chinese, Mughlai, Italian under one roof. It is in Center Stage Mall, Basement. Sector 18.

Desi Vibes . Indian Joint, Sector 18.

Yellow Chilli . Sanjiv Kapoor restaurant, Sector 18.

Pearl Regency . Ganga Shopping Complex, Sector 29. Offers Indian Mughlai and Chinese. One of the great places i have seen. please do vist.

Pizza Hut outlets in Sec 18, Center Stage Mall (again sector 18), Shopprix Mall, Spice Mall, Parshva Plaza (Sec 27), Sec 110 (In Front Of Kendriya Vihar Apt, Nr Sec-82).

Dominoes . Sec 18, Sec 51, Sec 110 (In Front Of Kendriya Vihar Apt, Nr Sec-82).

Nirulas . Sec 2.

Punjabi Galiyara . Sec 18.

Bamboo Shoots . Sec 18 - Some good chinese there!

Uncles Restaurant . Sec 11 - good food served here!

K65 Restaurant . Sec 65 - Homely food served here!

Lets Noodle . Sec 18 - Awesome Chinese Food!

' Pind balluchi The Great India place Mall-Awesome panjabi food!

Splurge Edit

Punjabi by Nature . P-19, Sector 18 ( Atta Market ), tel. +91-120-4250111. The local outlet of the exuberantly hip Punjabi chain, serving up tandoori lobster and vodka golgappas next to crazy decor that's half dhaba . half crystal chandeliers and indoor waterfalls. While there's a premium to pay for the surroundings, the food is solid and the makki ki roti with sarson ka saag is worth the price tag. Rs.500, more if you sample the booze or seafood.

Chor Bizarre . Sector 16

Octopus . Sector 16

The Great Kebab factory . Sector 18

Moti Mahal . Sector 18 - For absolutely amazing Mughlai cuisine!

Drink Edit

Alcohol in Uttar Pradesh is somewhat pricier than in Delhi. The main nightlife district is Atta Market (Sector 18). It can be compared to the Dadar market in Mumbai

Flluid . Mosaic Hotel, Sector 18. Slick two-floor bar and nightclub that looks somewhat like an Arctic cavern, with billowing white shapes and blue lighting. Kingfisher Rs.200.

Ice Cubes . Sector 38-A.

Pacific Blues . Sector 18.

Anchor . Sector 18.

Vinnys . Sector 18.

Patiala Kings . Sector 18.

Chicane . Sector 25A, Spice Mall.

Pearl's Regency . Sector 29, Ganga Shopping Complex.

Mamouchee. 4th Floor Centre Stage Mall. offers quite good range of cocktails. On the food side. good lebanese options  edit

quantum ( elevate ), centerstage mall ( sector 18 ), [7]. arguably one of the best nightclubs in Delhi-NCR.  edit

Sleep Edit

Budget Edit

Mid-range Edit

Nirulas. Sec 2 ( Next to main Metro Line ). Oldest hotel of Noida. Possibly 3-star. Good fast food joint, pastry shop, bakery, Tea/Coffee Lounge, Bar. 5000.  edit

Fortune Inn Garzia . Sec-18.

Splurge Edit

Mosaic Hotel . Sector 18, [8]. Formerly the Shipra Hotel, but after a 2006 renovation is now a "business boutique" hotel with the appearance of a hip nightclub (indeed, Flluid is in the basement) and the price of a big-city Indian business hotel. Rooms are modern and comfortable, service is friendly and efficient, but wireless Internet is expensive and patchy. From US$200 up.

Park Plaza . C Block, Sec-55, tel. + 91-12-04678888, [9] .

Radisson Noida . [10]. Noida's first but no longer only branded hotel. Weekday rates from US$400 up.

Get out Edit

Budenite, Budenite

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Rhinocort is used for the control of asthma in persons requiring continuous, prolonged treatment. Such patients may include those with frequent asthmatic episodes requiring bronchodilators, or those with asthmatic episodes at night.

Use Rhinocort as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Hold the device upright while using. If the inhaler device is dropped or shaken, or if you accidentally breathe into the device after the dose has been loaded, you will lose the dose. Load another dose. Do not use the inhaler if it has been damaged or if the mouthpiece has come off. Inhale this medication by mouth, usually once or twice daily or as directed by your doctor. Inhale deeply and forcefully while using the device. Turn your mouth away from the device to breathe out before inhaling.

Keep track of each dose of medication you use. Discard the device after it has delivered the labeled number of doses or when the red mark reaches the bottom of the dose indicator window. The dosage is based on your medical condition and response to treatment. Use this medication regularly to get the most benefit from it.

Do not increase your dose or use this drug more often or for longer than prescribed.

Take Rhinocort as directed by your doctor.

Budesonide is used to prevent asthmatic attacks and should not be used to treat an acute attack of asthma. The Turbuhaler is used for individuals six years of age or older. Effects can be seen within 24 hours, but maximum effects may not be seen for 1-2 weeks or longer. Doses vary widely. Adults usually receive 1 to 4 actuations (puffs) twice daily. Children usually receive 1 to 2 puffs twice daily. For those with mild asthma, treatment once daily may be sufficient.

Budesonide should be stored at room temperature, 20-25 C (68-77 F).

Before using budesonide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as lactose, milk proteins found in some brands), which can cause allergic reactions or other problems.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: eye disease (such as cataracts. glaucoma), high blood pressure, liver disease, thyroid problems, diabetis, stomach/intestinal problems, bone loss (osteoporosis), current/past infections (such as tuberculosis, positive tuberculosis test, herpes, fungal), bleeding problems, mental/mood conditions (such as psychosis, anxiety, depression).

Before having surgery or emergency treatment, or if you get a serious illness/injury, tell your doctor or dentist that you are using this medication or have used a corticosteroid taken by mouth within the past 12 months. Tell your doctor immediately if you develop unusual/extreme tiredness or weight loss.

Tell your doctor if you are pregnant before using this medication. Infants born to mothers who have used corticosteroids for a long time may have hormone problems.

Some products that may interact with this drug include: aldesleukin, other drugs that weaken the immune system (such as azathioprine, cyclosporine, cancer, chemotherapy), mifepristone. Other medications can affect the removal of budesonide from your body, which may affect how budesonide works. Examples include azole antifungals (such as ketokonazole), boceprevir, macrolide antibiotics (such as erythromycin, rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine. phenytoin), among others.

Dry/irritated throat, hoarseness, voice changes, bad taste in the mouth, runny nose, or nosebleeds may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Many people using this medication do not have serious side effects. Infrequently, this medication may cause severe sudden worsening of breathing problems/asthma immediately after use. If you have sudden worsening of breathing, use your quick-relief inhaler and seek immediate medical attention. Because this drug works by weakening the immune system, it may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor immediately if you have any signs of infection (such as ear pain, sore throat, fever, chills).

Use of this medication for prolonged or repeated periods may result in yeast infection. Contact your doctor if you notice white patches in your mouth or on your tongue.

Tell your doctor immediately if any of these rare but serious side effects occur: unusual tiredness, vision problems, easy bruising/bleeding, puffy face, unusual hair growth, mental/mood changes (such as depression, mood swings, agitation), muscle weakness/pain, thinning skin, slow wound healing, increased thirst/urination. A very serious allergic reaction to this drug is rare.

Seek immediate medical attention if you notice any symptoms of a serious allergic reaction: rash/itching, swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

Define Body - Mind, Barre Classes, Yoga Classes, Spin Classes, Difin

At DEFINE body & mind, our mission is to educate people on how to become their absolute best! Clients can enjoy a combination of barre, cycling, yoga, trampoline, hammock, and so much more… All Under One Roof!

Our classes, products, and programs work synergistically to deliver total wellness through strength, length, and balance in an inspiring atmosphere where fitness is fun!

Define body

A balanced class of strength and flexibility combining Pilates, yoga and ballet.

Define mind

A soothing class focused on gaining flexibility, refreshing the body, and calming the mind.

Define revolution

DEFINE rev . like indoor cycling, combines isometrics with cardio blasting, high intensity fun.

Define bounce

A fun, high-energy, fat-burning, 45-minute class of strength building for body, mind and heart.

September 16, 2016 REV IT UP IN PINK!

In recognition of Breast Cancer Awareness month, on October 15th at 8pm fitness enthusiasts and those new to fitness (and everyone in between) are invited to show their true pink colors, jam out to Coldplay, and join DEFINE body & mind to support The Rose (the leading nonprofit breast healthcare organization in southeast Texas) during a 1-hour revolution spinning workshop and […]

September 15, 2016 Stay Active: Even In The Heat!

The hot Houston days are still lingering with us. With that comes the continuation of social media car dashboard photos displaying 100+ degrees and rants about just how hot it truly is outside. Houstonians, are you really that surprised by the heat? It seems that even after summer comes to an end, the same rumblings […]

September 13, 2016 Importance of the Perfect Playlist to Maximize your Workout!

Long before I was an instructor at DEFINE body & mind, I knew music and a good playlist was an integral tool into how I performed during a workout. Just to give you a sense of how long I have been making playlists—let’s take a jog down memory lane. This blog will no doubt date […]

CLASSES & SCHEDULES

Click on the class icons to find out more about each class, check out the schedule or register.

We're Social

Get In Touch

Enjoy your first class at define free!

Sign up for our mailing list and get a FREE SINGLE CLASS CERTIFICATE for your first visit at any DEFINE body & mind location, as well as the latest info, news & special offers available.

Ready to be your absolute best?

Now is the time to enjoy a combination of barre, cycling, yoga, trampoline, hammock. and so much more. All Under One Roof!

Claim your certificate by completing the form below

Success Time to define your life!

Thank you for subscribing to DEFINE body & mind

Your pass has been sent to the email address you provided. Please check your spam or junk folder if the email is not in your inbox. Please be on the lookout for your FREE SINGLE CLASS CERTIFICATE and more information on what makes DEFINE your perfect studio to reDEFINE your fitness and wellness goals!

Your subscription not only entitles you to a FREE SINGLE CLASS CERTIFICATE, it also entitles you to receive valuable email newsletters, announcements, offers, and health, beauty, & wellness tips.

You can cancel your subscription or change your preference by clicking Unsubscribe link at the bottom of any email message we send in the future. Thank you and welcome to the start of defining your journey to total wellness, body & mind.

To activate your pass:

Print the email you received and bring it to the club OR show the email on your smart phone to a staff member at DEFINE body & mind

Isoniazid Syrup Indications, Side Effects, Warnings, Isonid

Isoniazid syrup

Generic Name: isoniazid (EYE-soe-NYE-a-zid) Brand Name: Generic only. No brands available.

Isoniazid syrup may cause severe and sometimes fatal liver problems (eg, hepatitis). The risk of liver problems is greater in patients older than 35 years old. It may also be increased by daily use of alcohol, long-term liver problems or unsanitary injectable drug use. Women, especially those who are black, are Hispanic, or have just had a baby, may also be at increased risk. Hepatitis can develop at any time during treatment but usually occurs during the first 3 months. Your doctor will monitor your liver function and discuss your progress every month.

Contact your doctor right away if you develop unusual fatigue, weakness or fever that lasts longer than 3 days, general feeling of discomfort, loss of appetite, nausea, vomiting, numbness or tingling of the hands or feet, dark urine, yellowing of the skin or eyes, or stomach pain or tenderness.

Patients with active liver problems should not use isoniazid syrup.

Isoniazid syrup is used for:

Treating or preventing tuberculosis (TB). If you are using isoniazid syrup to treat TB, it should always be used along with another medicine.

Isoniazid syrup is an antibacterial. It works by killing TB bacteria.

Do NOT use isoniazid syrup if:

you are allergic to any ingredient in isoniazid syrup or have had severe side effects from isoniazid, such as drug fever, chills, or arthritis

you have severe liver damage, active liver disease, or liver damage from previous use of isoniazid syrup

you have a history of hepatitis caused by any medicine

Contact your doctor or health care provider right away if any of these apply to you.

Before using isoniazid syrup:

Some medical conditions may interact with isoniazid syrup. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have diabetes, kidney problems, nerve problems (eg, neuropathy) or risk of nerve problems, HIV, or a history of liver problems

if you have a history of alcohol or other substance abuse, have unsanitary injectable drug habits, or drink alcohol daily

if you are older than 35 years old, you have recently given birth, or you have previously taken isoniazid syrup

Some MEDICINES MAY INTERACT with isoniazid syrup. Tell your health care provider if you are taking any other medicines, especially any of the following:

Acetaminophen, anticoagulants (eg, warfarin), carbamazepine, hydantoins (eg, phenytoin), rifampin, theophylline, or valproic acid because the risk of their side effects may be increased by isoniazid syrup

Ketoconazole because its effectiveness may be decreased by isoniazid syrup

This may not be a complete list of all interactions that may occur. Ask your health care provider if isoniazid syrup may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use isoniazid syrup:

Use isoniazid syrup as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take isoniazid syrup by mouth on an empty stomach at least 1 hour before or 2 hours after eating.

If you also take an antacid, take isoniazid syrup at least 1 hour before you take the antacid.

Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

Continue to take isoniazid syrup even if you feel well. Do not miss any doses.

If you miss a dose of isoniazid syrup, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use isoniazid syrup.

Important safety information:

Check with your doctor before drinking alcohol while taking isoniazid syrup. Alcohol may increase the risk of liver problems. If you have a history of alcohol abuse, you may also be at increased risk of developing nerve problems from isoniazid syrup. Notify your doctor if you notice any unusual tingling in your hands or feet.

If you have a history of diabetes, alcohol abuse, or poor nutrition, your doctor may recommend that you also take vitamin B 6 while you are taking isoniazid syrup. This may help to decrease your risk of nerve problems. Discuss any questions with your doctor.

Do not eat foods high in tyramine while you take isoniazid syrup. Eating foods high in tyramine (eg, aged cheeses, red wines, beer, certain meats and sausages, liver, sour cream, soy sauce, raisins, bananas, avocados) while you take isoniazid syrup may cause severe high blood pressure. Seek medical attention at once if symptoms of severe high blood pressure occur. These may include severe headache, fast or irregular heartbeat, sore or stiff neck, nausea, vomiting, sweating, enlarged pupils, or sensitivity to light.

Do not eat foods high in histamine while you take isoniazid syrup. Eating foods high in histamine (eg, skipjack, tuna, tropical fish) while you take isoniazid syrup may cause low blood pressure, irregular heartbeat, headache, sweating, or flushing. Contact your doctor at once if any of these symptoms occur.

Ask your health care provider for a complete list of foods you should avoid while you are taking isoniazid syrup.

Isoniazid syrup only works against TB bacteria; it does not treat viral infections (eg, the common cold).

Be sure to take isoniazid syrup for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

Diabetes patients - Isoniazid syrup may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before adjusting the dose of your diabetes medicine. You may also be at increased risk of developing nerve problems from isoniazid syrup. Contact your doctor if you notice any unusual tingling in your hands or feet.

Lab tests, including liver function and eye exams, may be performed while you take isoniazid syrup. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

Use isoniazid syrup with caution in BLACK and HISPANIC WOMEN; they may have a greater risk of severe liver problems from isoniazid syrup.

Use isoniazid syrup with caution in patients older than 35 years old; they may have a greater risk of severe liver problems from isoniazid syrup.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of taking isoniazid syrup while you are pregnant. Isoniazid syrup is found in breast milk. If you are or will be breast-feeding while you take isoniazid syrup, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of isoniazid syrup:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Mild stomach upset.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; chills or fever; dark urine; general feeling of discomfort; increased thirst or urination; joint pain or swelling; loss of appetite; memory problems; mental or mood changes; nausea; seizures; stomach pain or tenderness; symptoms of low vitamin B 6 levels (eg, confusion, cracks in the corners of the mouth, irritability, mouth redness or soreness, scaly rash); tingling or numbness in the hands or feet; unusual bruising or bleeding; unusual tiredness or weakness; vomiting; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA .

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center. or emergency room immediately. Symptoms may include blurred vision; dizziness; hallucinations; loss of consciousness; nausea; seizures; slurred speech; symptoms of high blood sugar (eg, confusion, increased thirst or urination, rapid breathing, unusual drowsiness); very slow breathing; vomiting.

Proper storage of isoniazid syrup:

Store isoniazid syrup between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep isoniazid syrup out of the reach of children and away from pets.

General information:

If you have any questions about isoniazid syrup, please talk with your doctor, pharmacist, or other health care provider.

Isoniazid syrup is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information should not be used to decide whether or not to take isoniazid syrup or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about isoniazid syrup. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to isoniazid syrup. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using isoniazid syrup.

Review Date: August 8, 2016

Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using this medicine.

More about isoniazid

Goodbye From, Justin

The Justin. tv website, mobile apps, and APIs are no longer in service. Thank you sincerely for seven years of live video memories.

Why is Justin. tv being shut down?

Justin. tv pioneered live video on the Internet and spawned one of the largest video platforms ever: Twitch. Justin. tv was officially renamed Twitch Interactive Inc. in February of 2014 and Twitch is now the focus of the company's resources. Unfortunately that means we need to shut down Justin. tv. We thank all of our broadcasters and viewers for 7 years of live video memories.

What will happen to my account?

Your account is now closed, and you will be unable to access any settings or content. If you would like to join Twitch with your Justin. tv user name, convert your account now. If you used your Justin. tv account to login to Twitch, please convert your account to retain your user name, past broadcasts, and notiifcation settings. Account must be converted by February 13th, 2015. On February 13th, 2015, all remaining Justin. tv accounts will be deleted. Usernames of deleted accounts will remain locked. Please be reminded today, Twitch is a site for gaming-related content only. Refer to the Twitch TOS for more info on content guidelines.

Can I retrieve my Justin. tv videos?

Unfortunately, videos on Justin. tv are no longer accessible for download. Video archiving and VODs were removed on June 15, 2014.

I'm an active Pro Account User, will I be refunded?

Yes. You should have already received an email communicating the cancellation and refund process.

Will the mobile apps, APIs, broadcast tool, or any other components of the site work?

Where can I broadcast now?

If you are interested in broadcasting any video game, or gaming-related content, please check out www. Twitch. tv. For other types of content, there are a number of live sites still out there who support live video broadcasting: YouTube, Ustream and Livestream, for instance.

I have a JTV account, can I transfer it to Twitch?

Absolutely! To move your account to Twitch, please complete this form. Your new Twitch account will be available immediately. Accounts must be converted by February 13th, 2015.

What information will be transferred?

You will keep your username and email address associated with your account.

Your account will be disconnected from Facebook (if currently connected). You can reconnect once your account is on Twitch.

You will continue to follow any Twitch channel you are currently following.

Any channel you followed on JTV will NOT appear on your Twitch following list, unless that channel is also transferred to Twitch.

You will NOT keep your JTV followers, unless your followers also transfer to Twitch.

VODs will not be transferred to Twitch.

I purchased Turbo or a channel subscription on Twitch with my Justin. tv account. Now what?

We have already moved your account to Twitch!

Mebeverine Hydrochloride Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, Meverine

Medicines & treatments centre

MEBEVERINE HYDROCHLORIDE USES

What is it used for?

Mebeverine is used to treat a number of problems.

It is a direct relaxant of gut (intestinal) muscle, and is sometimes known as an antispasmodic drug.

It is used to relax the muscles of the intestine and to treat symptoms of irritable bowel syndrome and related conditions.

In general this drug is used to manage the symptoms of irritable bowel syndrome, a common intestinal condition which causes spasm and pain in the intestine, as well as stomach pain. persistent diarrhoea (sometimes alternating with periods of constipation ) and wind (flatulence ).

Benefits of being on this drug include reducing the painful and troublesome symptoms of irritable bowel syndrome.

Listed below are the typical uses of mebeverine.

Relief from the symptoms of irritable bowel syndrome as well as other conditions usually included in this grouping, such as chronic irritable colon. spastic constipation. mucous colitis and spastic colitis.

On occasion your doctor may prescribe this medicine to treat a condition not on the above list.

HOW TO USE/TAKE

How often do I take it?

Take this medication orally usually two - or three-times daily, about 20–30 minutes before meals. Tablets or capsules should be taken whole with a glass of water.

Use this medication regularly in order to get the most benefit from it.

Remember to use it at the same time each day - unless specifically told otherwise by your doctor.

It may take some time before the full benefit of this drug takes effect.

Certain medical conditions may require different dosage instructions as directed by your doctor.

What dose?

Dosage is based on your age, gender, medical condition, response to therapy, and use of certain interacting medicines.

Do I need to avoid anything?

No. Consult your doctor or pharmacist for more details.

When can I stop?

It is important to continue taking this medication even if you feel well, unless your doctor tells you to stop.

MEBEVERINE HYDROCHLORIDE SIDE EFFECTS

If any of these persist or you consider them severe then inform your doctor.

Tell your doctor immediately if you develop any of the following symptoms: none listed.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

A serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling (especially of the face /tongue /throat), dizziness. trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

The Yellow Card Scheme allows you to report suspected side effects from any type of medicine (which includes vaccines, herbals and over the counter medicines) that you are taking. It is run by the medicines safety watchdog called the Medicines and Healthcare products Regulatory agency (MHRA). Please report any suspected side effect on the Yellow Card Scheme website.

MEBEVERINE HYDROCHLORIDE PRECAUTIONS

Before taking mebeverine, tell your doctor or pharmacist if you are allergic to it; or to other antispasmodic drugs; or if you have any other allergies.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: paralytic ileus (lack of bowel movements, leading to blockage of the gut).

Before using this medication, tell your doctor or pharmacist your medical history, especially any of the following: any bleeding disorders (especially bleeding from the gut), severe constipation, having difficulty or pain when passing urine (water), recently had a fever, bloody stools. or have had abnormal vaginal bleeding or discharge, if you have developed any new symptoms or you your symptoms have become worse

Before having surgery, tell your doctor or dentist that you are taking this medication.

Does alcohol intake affect this drug?

Alcohol intake is not known to affect mebeverine.

The elderly. mebeverine should be used with caution in the elderly as it may cause more side-effects than in younger patients.

Pregnancy and breastfeeding - please ensure you read the detailed information below

PREGNANCY

Mebeverine safety has not been established in pregnancy. Ask your doctor or pharmacist if you have any doubts or questions about this.

It is sensible to limit use of medication during pregnancy whenever possible. However, your doctor may decide that the benefits outweigh the risks in individual circumstances and after a careful assessment of your specific health situation.

If you have any doubts or concerns you are advised to discuss the medicine with your doctor or pharmacist.

BREAST FEEDING

Mebeverine safety has not been established in breastfeeding. Ask your doctor or pharmacist if you have any doubts or questions about this.

It is sensible to limit use of medication during breastfeeding whenever possible. However, your doctor may decide that the benefits outweigh the risks in individual circumstances and after a careful assessment of your specific health situation.

If you have any doubts or concerns you are advised to discuss the medicine with your doctor or pharmacist.

MEBEVERINE HYDROCHLORIDE INTERACTIONS

Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with them first.

This drug should not be used with the following medications because very serious, possibly fatal interactions may occur: none known.

Before using this medication, tell your doctor or pharmacist of all prescription and non-prescription/herbal products you may use, especially of:

none known

This information does not contain all possible interactions. Therefore, before using mebeverine, tell your doctor or pharmacist of all the products you use.

MEBEVERINE HYDROCHLORIDE OVERDOSE

There are no reports of overdoses with this drug.

If you think you, or someone you care for, might have accidentally taken more than the recommended dose of mebeverine or intentional overdose is suspected, contact your local hospital, GP or if in England call 111. In Scotland call NHS 24. In Wales, call NHS Direct Wales. In the case of medical emergencies, always dial 999.

MISSED DOSE

If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Losartan - Fda Prescribing Information, Side Effects And Uses, Losartil

Losartan

Indications and Usage for Losartan

Hypertension

Losartan is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Losartan.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e. g. on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Losartan may be administered with other antihypertensive agents.

Hypertensive Patients with Left Ventricular Hypertrophy

Losartan is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ] .

Nephropathy in Type 2 Diabetic Patients

Losartan is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, Losartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.3) ] .

Losartan Dosage and Administration

Hypertension

The usual starting dose of Losartan is 50 mg once daily. The dosage can be increased to a maximum dose of 100 mg once daily as needed to control blood pressure [see Clinical Studies (14.1) ]. A starting dose of 25 mg is recommended for patients with possible intravascular depletion (e. g. on diuretic therapy).

The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5) ]. Dosage should be adjusted according to blood pressure response. Doses above 1.4 mg per kg (or in excess of 100 mg) daily have not been studied in pediatric patients [see Clinical Pharmacology (12.3). Clinical Studies (14.1). and Warnings and Precautions (5.2) ] .

Losartan is not recommended in pediatric patients less than 6 years of age or in pediatric patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m 2 [see Use in Specific Populations (8.4). Clinical Pharmacology (12.3). and Clinical Studies (14) ] .

Hypertensive Patients with Left Ventricular Hypertrophy

The usual starting dose is 50 mg of Losartan once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of Losartan should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response [see Clinical Studies (14.2) ] .

Nephropathy in Type 2 Diabetic Patients

The usual starting dose is 50 mg once daily. The dose should be increased to 100 mg once daily based on blood pressure response [see Clinical Studies (14.3) ] .

Dosage Modifications in Patients with Hepatic Impairment

In patients with mild-to-moderate hepatic impairment the recommended starting dose of Losartan is 25 mg once daily. Losartan has not been studied in patients with severe hepatic impairment [see Use in Special Populations (8.8) and Clinical Pharmacology (12.3) ] .

Dosage Forms and Strengths

• 25 mg are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 277” on one side and plain on the other side. • 50 mg are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 125” on one side and scored on the other side.

100 mg are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 357” on one side and plain on the other side.

Contraindications

Losartan is contraindicated:

• In patients who are hypersensitive to any component of this product.

For coadministration with aliskiren in patients with diabetes.

Warnings and Precautions

Fetal Toxicity

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Losartan as soon as possible [see Use in Specific Populations (8.1) ] .

Hypotension in Volume - or Salt-Depleted Patients

In patients with an activated renin-angiotensin system, such as volume - or salt-depleted patients (e. g. those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Losartan. Correct volume or salt depletion prior to administration of Losartan [see Dosage and Administration (2.1) ] .

Renal Function Deterioration

Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e. g. patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on Losartan. Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on Losartan [see Drug Interactions (7.3) and Use in Specific Populations (8.7) ] .

Hyperkalemia

Monitor serum potassium periodically and treat appropriately. Dosage reduction or discontinuation of Losartan may be required [see Adverse Reactions (6.1) ] .

Adverse Reactions

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Losartan has been evaluated for safety in more than 3300 adult patients treated for essential hypertension and 4058 patients/subjects overall. Over 1200 patients were treated for over 6 months and more than 800 for over one year.

Treatment with Losartan was well-tolerated with an overall incidence of adverse events similar to that of placebo. In controlled clinical trials, discontinuation of therapy for adverse events occurred in 2.3% of patients treated with Losartan and 3.7% of patients given placebo. In 4 clinical trials involving over 1000 patients on various doses (10 to 150 mg) of Losartan potassium and over 300 patients given placebo, the adverse events that occurred in ≥2% of patients treated with Losartan and more commonly than placebo were: dizziness (3% vs. 2%), upper respiratory infection (8% vs. 7%), nasal congestion (2% vs. 1%), and back pain (2% vs. 1%).

The following less common adverse reactions have been reported:

Blood and Lymphatic System Disorders: Anemia.

Psychiatric Disorders: Depression.

Nervous System Disorders: Somnolence, headache, sleep disorders, paresthesia, migraine.

Ear and Labyrinth Disorders: Vertigo, tinnitus.

Cardiac Disorders: Palpitations, syncope, atrial fibrillation, CVA.

Respiratory, Thoracic and Mediastinal Disorders: Dyspnea.

Gastrointestinal Disorders: Abdominal pain, constipation, nausea, vomiting.

Skin and Subcutaneous Tissue Disorders: Urticaria, pruritus, rash, photosensitivity.

Musculoskeletal and Connective Tissue Disorders: Myalgia, arthralgia.

Reproductive System and Breast Disorders: Impotence.

General Disorders and Administration Site Conditions: Edema.

Persistent dry cough (with an incidence of a few percent) has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of Losartan on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to Losartan 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg hydrochlorothiazide (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below.

* Demographics = (89% Caucasian, 64% female) † Demographics = (90% Caucasian, 51% female)

These studies demonstrate that the incidence of cough associated with Losartan therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with hydrochlorothiazide or placebo therapy.

Cases of cough, including positive re-challenges, have been reported with the use of Losartan in postmarketing experience.

Hypertensive Patients with Left Ventricular Hypertrophy

In the Losartan Intervention for Endpoint (LIFE) study, adverse reactions with Losartan were similar to those reported previously for patients with hypertension.

Nephropathy in Type 2 Diabetic Patients

In the Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan (RENAAL) study involving 1513 patients treated with Losartan or placebo, the overall incidences of reported adverse events were similar for the two groups. Discontinuations of Losartan because of side effects were similar to placebo (19% for Losartan, 24% for placebo). The adverse events, regardless of drug relationship, reported with an incidence of ≥4% of patients treated with Losartan and occurring with ≥2% difference in the Losartan group vs. placebo on a background of conventional antihypertensive therapy, were asthenia/fatigue, chest pain, hypotension, orthostatic hypotension, diarrhea, anemia, hyperkalemia, hypoglycemia, back pain, muscular weakness, and urinary tract infection.

Postmarketing Experience

The following additional adverse reactions have been reported in postmarketing experience with Losartan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure:

General Disorders and Administration Site Conditions: Malaise.

Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported rarely in patients treated with Losartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schönlein purpura, has been reported. Anaphylactic reactions have been reported.

Metabolic and Nutrition: Hyponatremia.

Nervous System Disorders: Dysgeusia.

Drug Interactions

Agents Increasing Serum Potassium

Coadministration of Losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.

Lithium

Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including Losartan) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Losartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including Losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.

Dual Blockade of the Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of Losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of Losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

In most patients no benefit has been associated with using two RAS inhibitors concomitantly. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on Losartan and other agents that affect the RAS.

Do not coadminister aliskiren with Losartan in patients with diabetes. Avoid use of aliskiren with Losartan in patients with renal impairment (GFR <60 mL/min).

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category D

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Losartan as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the reninangiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue Losartan, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Losartan for hypotension, oliguria, and hyperkalemia [see Use in Specific Populations (8.4) ] .

Losartan potassium has been shown to produce adverse effects in rat fetuses and neonates, including decreased body weight, delayed physical and behavioral development, mortality and renal toxicity. With the exception of neonatal weight gain (which was affected at doses as low as 10 mg/kg/day), doses associated with these effects exceeded 25 mg/kg/day (approximately three times the maximum recommended human dose of 100 mg on a mg/m 2 basis). These findings are attributed to drug exposure in late gestation and during lactation. Significant levels of Losartan and its active metabolite were shown to be present in rat fetal plasma during late gestation and in rat milk.

Nursing Mothers

It is not known whether Losartan is excreted in human milk, but significant levels of Losartan and its active metabolite were shown to be present in rat milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Neonates with a history of in utero exposure to Losartan: If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.

Antihypertensive effects of Losartan have been established in hypertensive pediatric patients aged 6 to 16 years. Safety and effectiveness have not been established in pediatric patients under the age of 6 or in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m 2 [see Dosage and Administration (2.1). Clinical Pharmacology (12.3). and Clinical Studies (14.1) ] .

Geriatric Use

Of the total number of patients receiving Losartan in controlled clinical studies for hypertension, 391 patients (19%) were 65 years and over, while 37 patients (2%) were 75 years and over. In a controlled clinical study for renal protection in type 2 diabetic patients with proteinuria, 248 patients (33%) were 65 years and over. In a controlled clinical study for the reduction in the combined risk of cardiovascular death, stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy, 2857 patients (62%) were 65 years and over, while 808 patients (18%) were 75 years and over. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Race

In the LIFE study, Black patients with hypertension and left ventricular hypertrophy treated with atenolol were at lower risk of experiencing the primary composite endpoint compared with Black patients treated with Losartan (both cotreated with hydrochlorothiazide in the majority of patients). The primary endpoint was the first occurrence of stroke, myocardial infarction or cardiovascular death, analyzed using an intention-to-treat (ITT) approach. In the subgroup of Black patients (n=533, 6% of the LIFE study patients), there were 29 primary endpoints among 263 patients on atenolol (11%, 26 per 1000 patient-years) and 46 primary endpoints among 270 patients (17%, 42 per 1000 patient-years) on Losartan. This finding could not be explained on the basis of differences in the populations other than race or on any imbalances between treatment groups. In addition, blood pressure reductions in both treatment groups were consistent between Black and non-Black patients. Given the difficulty in interpreting subset differences in large trials, it cannot be known whether the observed difference is the result of chance. However, the LIFE study provides no evidence that the benefits of Losartan on reducing the risk of cardiovascular events in hypertensive patients with left ventricular hypertrophy apply to Black patients [see Clinical Studies (14.2) ] .

Renal Impairment

Patients with renal insufficiency have elevated plasma concentrations of Losartan and its active metabolite compared to subjects with normal renal function. No dose adjustment is necessary in patients with renal impairment unless a patient with renal impairment is also volume depleted [see Dosage and Administration (2.3). Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] .

Hepatic Impairment

The recommended starting dose of Losartan is 25 mg in patients with mild-to-moderate hepatic impairment. Following oral administration in patients with mild-to-moderate hepatic impairment, plasma concentrations of Losartan and its active metabolite were, respectively, 5 times and 1.7 times those seen in healthy volunteers. Losartan has not been studied in patients with severe hepatic impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] .

Overdosage

Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m 2 basis.

Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Neither Losartan nor its active metabolite can be removed by hemodialysis.

Losartan Description

Losartan potassium is an angiotensin II receptor blocker acting on the AT1 receptor subtype. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[ p -(o-1 H tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt.

Its molecular formula is C 22 H 22 ClKN 6 O, and its structural formula is:

Losartan potassium is a white to off-white powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone. Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Losartan.

Losartan Potassium Tablets USP are available for oral administration containing either 25 mg, 50 mg or 100 mg of Losartan potassium USP and the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, Opadry II (Green) and pregelatinized starch. Opadry II (Green) contains D&C Yellow #10, FD&C Blue #2, hypromellose, lactose monohydrate, polyethylene glycol, titanium dioxide and triacetin.

Losartan 25 mg, 50 mg and 100 mg tablets contain potassium in the following amounts: 2.12 mg (0.054 mEq), 4.24 mg (0.108 mEq) and 8.48 mg (0.216 mEq), respectively.

Each tablet meets the requirements of Test 2 for Dissolution in the USP Monograph for Losartan Potassium Tablets USP.

Losartan - Clinical Pharmacology

Mechanism of Action

Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e. g. vascular smooth muscle, adrenal gland). There is also an AT 2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Neither Losartan nor its principal active metabolite exhibits any partial agonist activity at the AT 1 receptor, and both have much greater affinity (about 1000-fold) for the AT 1 receptor than for the AT 2 receptor. In vitro binding studies indicate that Losartan is a reversible, competitive inhibitor of the AT 1 receptor. The active metabolite is 10 to 40 times more potent by weight than Losartan and appears to be a reversible, non-competitive inhibitor of the AT 1 receptor.

Neither Losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin), nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

Pharmacodynamics

Losartan inhibits the pressor effect of angiotensin II (as well as angiotensin I) infusions. A dose of 100 mg inhibits the pressor effect by about 85% at peak with 25 to 40% inhibition persisting for 24 hours. Removal of the negative feedback of angiotensin II causes a doubling to tripling in plasma renin activity and consequent rise in angiotensin II plasma concentration in hypertensive patients. Losartan does not affect the response to bradykinin, whereas ACE inhibitors increase the response to bradykinin. Aldosterone plasma concentrations fall following Losartan administration. In spite of the effect of Losartan on aldosterone secretion, very little effect on serum potassium was observed.

The effect of Losartan is substantially present within one week but in some studies the maximal effect occurred in 3 to 6 weeks. In long-term follow-up studies (without placebo control) the effect of Losartan appeared to be maintained for up to a year. There is no apparent rebound effect after abrupt withdrawal of Losartan. There was essentially no change in average heart rate in Losartan-treated patients in controlled trials.

Pharmacokinetics

Following oral administration, Losartan is well absorbed and undergoes substantial first-pass metabolism. The systemic bioavailability of Losartan is approximately 33%. Mean peak concentrations of Losartan and its active metabolite are reached in 1 hour and in 3 to 4 hours, respectively. While maximum plasma concentrations of Losartan and its active metabolite are approximately equal, the AUC (area under the curve) of the metabolite is about 4 times as great as that of Losartan. A meal slows absorption of Losartan and decreases its C max but has only minor effects on Losartan AUC or on the AUC of the metabolite (

10% decrease). The pharmacokinetics of Losartan and its active metabolite are linear with oral Losartan doses up to 200 mg and do not change over time.

The volume of distribution of Losartan and the active metabolite is about 34 liters and 12 liters, respectively. Both Losartan and its active metabolite are highly bound to plasma proteins, primarily albumin, with plasma free fractions of 1.3% and 0.2%, respectively. Plasma protein binding is constant over the concentration range achieved with recommended doses. Studies in rats indicate that Losartan crosses the blood-brain barrier poorly, if at all.

Losartan is an orally active agent that undergoes substantial first-pass metabolism by cytochrome P450 enzymes. It is converted, in part, to an active carboxylic acid metabolite that is responsible for most of the angiotensin II receptor antagonism that follows Losartan treatment. About 14% of an orally-administered dose of Losartan is converted to the active metabolite. In addition to the active carboxylic acid metabolite, several inactive metabolites are formed. In vitro studies indicate that cytochrome P450 2C9 and 3A4 are involved in the biotransformation of Losartan to its metabolites.

Total plasma clearance of Losartan and the active metabolite is about 600 mL/min and 50 mL/min, respectively, with renal clearance of about 75 mL/min and 25 mL/min, respectively. The terminal half-life of Losartan is about 2 hours and of the metabolite is about 6 to 9 hours. After single doses of Losartan administered orally, about 4% of the dose is excreted unchanged in the urine and about 6% is excreted in urine as active metabolite. Biliary excretion contributes to the elimination of Losartan and its metabolites. Following oral 14 C-labeled Losartan, about 35% of radioactivity is recovered in the urine and about 60% in the feces. Following an intravenous dose of 14 C-labeled Losartan, about 45% of radioactivity is recovered in the urine and 50% in the feces. Neither Losartan nor its metabolite accumulates in plasma upon repeated once-daily dosing.

Pediatric: Pharmacokinetic parameters after multiple doses of Losartan (average dose 0.7 mg/kg, range 0.36 to 0.97 mg/kg) as a tablet to 25 hypertensive patients aged 6 to 16 years are shown in Table 2 below. Pharmacokinetics of Losartan and its active metabolite were generally similar across the studied age groups and similar to historical pharmacokinetic data in adults. The principal pharmacokinetic parameters in adults and children are shown in the table below.

Table 2: Pharmacokinetic Parameters in Hypertensive Adults and Children Age 6 to 16 Following Multiple Dosing

* Mean ± standard deviation † Harmonic mean and standard deviation ‡ Median

The bioavailability of the suspension formulation was compared with Losartan tablets in healthy adults. The suspension and tablet are similar in their bioavailability with respect to both Losartan and the active metabolite [see Dosage and Administration (2.5) ] .

Geriatric and Gender: Losartan pharmacokinetics have been investigated in the elderly (65 to 75 years) and in both genders. Plasma concentrations of Losartan and its active metabolite are similar in elderly and young hypertensives. Plasma concentrations of Losartan were about twice as high in female hypertensives as male hypertensives, but concentrations of the active metabolite were similar in males and females. No dosage adjustment is necessary [see Dosage and Administration (2.1) ] .

Race: Pharmacokinetic differences due to race have not been studied [see Use in Specific Populations (8.6) ] .

Renal Insufficiency: Following oral administration, plasma concentrations and AUCs of Losartan and its active metabolite are increased by 50 to 90% in patients with mild (creatinine clearance of 50 to 74 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal insufficiency. In this study, renal clearance was reduced by 55 to 85% for both Losartan and its active metabolite in patients with mild or moderate renal insufficiency. Neither Losartan nor its active metabolite can be removed by hemodialysis [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7) ] .

Hepatic Insufficiency: Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of Losartan and its active metabolite were, respectively, 5-times and about 1.7-times those in young male volunteers. Compared to normal subjects the total plasma clearance of Losartan in patients with hepatic insufficiency was about 50% lower and the oral bioavailability was about doubled. Use a starting dose of 25 mg for patients with mild to moderate hepatic impairment. Losartan has not been studied in patients with severe hepatic impairment [see Dosage and Administration (2.4) and Use in Specific Populations (8.8) ] .

No clinically significant drug interactions have been found in studies of Losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. However, rifampin has been shown to decrease the AUC of Losartan and its active metabolite by 30% and 40%, respectively. Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of Losartan by approximately 70% following multiple doses. Conversion of Losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. The AUC of active metabolite following oral Losartan was not affected by erythromycin, an inhibitor of P450 3A4, but the AUC of Losartan was increased by 30%.

The pharmacodynamic consequences of concomitant use of Losartan and inhibitors of P450 2C9 have not been examined. Subjects who do not metabolize Losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of Losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Losartan potassium was not carcinogenic when administered at maximally tolerated dosages to rats and mice for 105 and 92 weeks, respectively. Female rats given the highest dose (270 mg/kg/day) had a slightly higher incidence of pancreatic acinar adenoma. The maximally tolerated dosages (270 mg/kg/day in rats, 200 mg/kg/day in mice) provided systemic exposures for Losartan and its pharmacologically active metabolite that were approximately 160 and 90 times (rats) and 30 and 15 times (mice) the exposure of a 50 kg human given 100 mg per day.

Losartan potassium was negative in the microbial mutagenesis and V-79 mammalian cell mutagenesis assays and in the in vitro alkaline elution and in vitro and in vivo chromosomal aberration assays. In addition, the active metabolite showed no evidence of genotoxicity in the microbial mutagenesis, in vitro alkaline elution, and in vitro chromosomal aberration assays.

Fertility and reproductive performance were not affected in studies with male rats given oral doses of Losartan potassium up to approximately 150 mg/kg/day. The administration of toxic dosage levels in females (300/200 mg/kg/day) was associated with a significant (p<0.05) decrease in the number of corpora lutea/female, implants/female, and live fetuses/female at C-section. At 100 mg/kg/day only a decrease in the number of corpora lutea/female was observed. The relationship of these findings to drug-treatment is uncertain since there was no effect at these dosage levels on implants/pregnant female, percent post-implantation loss, or live animals/litter at parturition. In nonpregnant rats dosed at 135 mg/kg/day for 7 days, systemic exposure (AUCs) for Losartan and its active metabolite were approximately 66 and 26 times the exposure achieved in man at the maximum recommended human daily dosage (100 mg).

Clinical Studies

Hypertension

The antihypertensive effects of Losartan were demonstrated principally in 4 placebo-controlled, 6- to 12-week trials of dosages from 10 to 150 mg per day in patients with baseline diastolic blood pressures of 95 to 115. The studies allowed comparisons of two doses (50 to 100 mg/day) as once-daily or twice-daily regimens, comparisons of peak and trough effects, and comparisons of response by gender, age, and race. Three additional studies examined the antihypertensive effects of Losartan and hydrochlorothiazide in combination.

The 4 studies of Losartan monotherapy included a total of 1075 patients randomized to several doses of Losartan and 334 to placebo. The 10 mg and 25-mg doses produced some effect at peak (6 hours after dosing) but small and inconsistent trough (24 hour) responses. Doses of 50 mg, 100 mg and 150 mg once daily gave statistically significant systolic/diastolic mean decreases in blood pressure, compared to placebo in the range of 5.5 to 10.5/3.5 to 7.5 mmHg, with the 150-mg dose giving no greater effect than 50 mg to 100 mg. Twice-daily dosing at 50 mg to 100 mg/day gave consistently larger trough responses than once-daily dosing at the same total dose. Peak (6 hour) effects were uniformly, but moderately, larger than trough effects, with the trough-to-peak ratio for systolic and diastolic responses 50 to 95% and 60 to 90%, respectively.

Addition of a low dose of hydrochlorothiazide (12.5 mg) to Losartan 50 mg once daily resulted in placebo-adjusted blood pressure reductions of 15.5/9.2 mmHg.

Analysis of age, gender, and race subgroups of patients showed that men and women, and patients over and under 65, had generally similar responses. Losartan was effective in reducing blood pressure regardless of race, although the effect was somewhat less in Black patients (usually a low-renin population).

The antihypertensive effect of Losartan was studied in one trial enrolling 177 hypertensive pediatric patients aged 6 to 16 years old. Children who weighed <50 kg received 2.5 mg, 25 mg or 50 mg of Losartan daily and patients who weighed ≥50 kg received 5 mg, 50 mg or 100 mg of Losartan daily. Children in the lowest dose group were given Losartan in a suspension formulation [see Dosage and Administration (2.1) ]. The majority of the children had hypertension associated with renal and urogenital disease. The sitting diastolic blood pressure (SiDBP) on entry into the study was higher than the 95th percentile level for the patient’s age, gender, and height. At the end of three weeks, Losartan reduced systolic and diastolic blood pressure, measured at trough, in a dose-dependent manner. Overall, the two higher doses (25 mg to 50 mg in patients <50 kg; 50 mg to 100 mg in patients ≥50 kg) reduced diastolic blood pressure by 5 to 6 mmHg more than the lowest dose used (2.5 mg in patients <50 kg; 5 mg in patients ≥50 kg). The lowest dose, corresponding to an average daily dose of 0.07 mg/kg, did not appear to offer consistent antihypertensive efficacy. When patients were randomized to continue Losartan at the two higher doses or to placebo after 3 weeks of therapy, trough diastolic blood pressure rose in patients on placebo between 5 and 7 mmHg more than patients randomized to continuing Losartan. When the low dose of Losartan was randomly withdrawn, the rise in trough diastolic blood pressure was the same in patients receiving placebo and in those continuing Losartan, again suggesting that the lowest dose did not have significant antihypertensive efficacy. Overall, no significant differences in the overall antihypertensive effect of Losartan were detected when the patients were analyzed according to age (<, ≥12 years old) or gender. While blood pressure was reduced in all racial subgroups examined, too few non-White patients were enrolled to compare the dose-response of Losartan in the non-White subgroup.

Hypertensive Patients with Left Ventricular Hypertrophy

The LIFE study was a multinational, double-blind study comparing Losartan and atenolol in 9193 hypertensive patients with ECG-documented left ventricular hypertrophy. Patients with myocardial infarction or stroke within six months prior to randomization were excluded. Patients were randomized to receive once daily Losartan 50 mg or atenolol 50 mg. If goal blood pressure (<140/90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of Losartan or atenolol was then increased to 100 mg once daily. If necessary, other antihypertensive treatments (e. g. increase in dose of hydrochlorothiazide therapy to 25 mg or addition of other diuretic therapy, calcium-channel blockers, alpha-blockers, or centrally acting agents, but not ACE inhibitors, angiotensin II antagonists, or beta-blockers) were added to the treatment regimen to reach the goal blood pressure.

Of the randomized patients, 4963 (54%) were female and 533 (6%) were Black. The mean age was 67 with 5704 (62%) age ≥65. At baseline, 1195 (13%) had diabetes, 1326 (14%) had isolated systolic hypertension, 1469 (16%) had coronary heart disease, and 728 (8%) had cerebrovascular disease. Baseline mean blood pressure was 174/98 mmHg in both treatment groups. The mean length of follow-up was 4.8 years. At the end of study or at the last visit before a primary endpoint, 77% of the group treated with Losartan and 73% of the group treated with atenolol were still taking study medication. Of the patients still taking study medication, the mean doses of Losartan and atenolol were both about 80 mg/day, and 15% were taking atenolol or Losartan as monotherapy, while 77% were also receiving hydrochlorothiazide (at a mean dose of 20 mg/day in each group). Blood pressure reduction measured at trough was similar for both treatment groups but blood pressure was not measured at any other time of the day. At the end of study or at the last visit before a primary endpoint, the mean blood pressures were 144.1/81.3 mmHg for the group treated with Losartan and 145.4/80.9 mmHg for the group treated with atenolol; the difference in systolic blood pressure (SBP) of 1.3 mmHg was significant (p<0.001), while the difference of 0.4 mmHg in diastolic blood pressure (DBP) was not significant (p=0.098).

The primary endpoint was the first occurrence of cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction. Patients with nonfatal events remained in the trial, so that there was also an examination of the first event of each type even if it was not the first event (e. g. a stroke following an initial myocardial infarction would be counted in the analysis of stroke). Treatment with Losartan resulted in a 13% reduction (p=0.021) in risk of the primary endpoint compared to the atenolol group (see Figure 1 and Table 3); this difference was primarily the result of an effect on fatal and nonfatal stroke. Treatment with Losartan reduced the risk of stroke by 25% relative to atenolol (p=0.001) (see Figure 2 and Table 3).

Figure 1: Kaplan-Meier estimates of the primary endpoint of time to cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction in the groups treated with Losartan and atenolol. The Risk Reduction is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.

Figure 2: Kaplan-Meier estimates of the time to fatal/nonfatal stroke in the groups treated with Losartan and atenolol. The Risk Reduction is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.

Table 3 shows the results for the primary composite endpoint and the individual endpoints. The primary endpoint was the first occurrence of stroke, myocardial infarction or cardiovascular death, analyzed using an ITT approach. The table shows the number of events for each component in two different ways. The Components of Primary Endpoint (as a first event) counts only the events that define the primary endpoint, while the Secondary Endpoints count all first events of a particular type, whether or not they were preceded by a different type of event.

Table 3: Incidence of Primary Endpoint Events

1. Rate per 1000 patient-years of follow-up 2. Adjusted for baseline Framinham risk score and level of electrocardiographic left ventricular hypertrophy 3. Death due to heart failure, non-coronary vascular disease, pulmonary embolism, or a cardiovascular cause other than stroke or coronary heart disease

Although the LIFE study favored Losartan over atenolol with respect to the primary endpoint (p=0.021), this result is from a single study and, therefore, is less compelling than the difference between Losartan and placebo. Although not measured directly, the difference between Losartan and placebo is compelling because there is evidence that atenolol is itself effective (vs. placebo) in reducing cardiovascular events, including stroke, in hypertensive patients.

Other clinical endpoints of the LIFE study were: total mortality, hospitalization for heart failure or angina pectoris, coronary or peripheral revascularization procedures, and resuscitated cardiac arrest. There were no significant differences in the rates of these endpoints between the Losartan and atenolol groups.

For the primary endpoint and stroke, the effects of Losartan in patient subgroups defined by age, gender, race and presence or absence of isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD) are shown in Figure 3 below. Subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.

Figure 3: Primary Endpoints Events † Within Demographic Subgroups

# Other includes Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, European.

† Adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.

Symbols are proportional to sample size.

Nephropathy in Type 2 Diabetic Patients

The RENAAL study was a randomized, placebo-controlled, double-blind, multicenter study conducted worldwide in 1513 patients with type 2 diabetes with nephropathy (defined as serum creatinine 1.3 to 3 mg/dL in females or males ≤60 kg and 1.5 to 3 mg/dL in males >60 kg and proteinuria [urinary albumin to creatinine ratio ≥300 mg/g]).

Patients were randomized to receive Losartan 50 mg once daily or placebo on a background of conventional antihypertensive therapy excluding ACE inhibitors and angiotensin II antagonists. After one month, investigators were instructed to titrate study drug to 100 mg once daily if the trough blood pressure goal (140/90 mmHg) was not achieved. Overall, 72% of patients received the 100-mg daily dose more than 50% of the time they were on study drug. Because the study was designed to achieve equal blood pressure control in both groups, other antihypertensive agents (diuretics, calcium-channel blockers, alpha - or beta-blockers, and centrally acting agents) could be added as needed in both groups. Patients were followed for a mean duration of 3.4 years.

The study population was diverse with regard to race (Asian 16.7%, Black 15.2%, Hispanic 18.3%, White 48.6%). Overall, 63.2% of the patients were men, and 66.4% were under the age of 65 years. Almost all of the patients (96.6%) had a history of hypertension, and the patients entered the trial with a mean serum creatinine of 1.9 mg/dL and mean proteinuria (urinary albumin/creatinine) of 1808 mg/g at baseline.

The primary endpoint of the study was the time to first occurrence of any one of the following events: doubling of serum creatinine, end-stage renal disease (ESRD) (need for dialysis or transplantation), or death. Treatment with Losartan resulted in a 16% risk reduction in this endpoint (see Figure 4 and Table 4). Treatment with Losartan also reduced the occurrence of sustained doubling of serum creatinine by 25% and ESRD by 29% as separate endpoints, but had no effect on overall mortality (see Table 4).

The mean baseline blood pressures were 152/82 mmHg for Losartan plus conventional antihypertensive therapy and 153/82 mmHg for placebo plus conventional antihypertensive therapy. At the end of the study, the mean blood pressures were 143/76 mmHg for the group treated with Losartan and 146/77 mmHg for the group treated with placebo.

Figure 4: Kaplan-Meier curve for the primary composite endpoint of doubling of serum creatinine, end stage renal disease (need for dialysis or transplantation) or death.

Table 4: Incidence of Primary Endpoint Events

The secondary endpoints of the study were change in proteinuria, change in the rate of progression of renal disease, and the composite of morbidity and mortality from cardiovascular causes (hospitalization for heart failure, myocardial infarction, revascularization, stroke, hospitalization for unstable angina, or cardiovascular death). Compared with placebo, Losartan significantly reduced proteinuria by an average of 34%, an effect that was evident within 3 months of starting therapy, and significantly reduced the rate of decline in glomerular filtration rate during the study by 13%, as measured by the reciprocal of the serum creatinine concentration. There was no significant difference in the incidence of the composite endpoint of cardiovascular morbidity and mortality.

The favorable effects of Losartan were seen in patients also taking other anti-hypertensive medications (angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors were not allowed), oral hypoglycemic agents and lipid-lowering agents.

For the primary endpoint and ESRD, the effects of Losartan in patient subgroups defined by age, gender and race are shown in Table 5 below. Subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.

Table 5: Efficacy Outcomes within Demographic Subgroups

Primary Composite Endpoint

Losartan Event Rate %

Placebo Event Rate %

Hazard Ratio (95% CI)

Losartan Event Rate %

Placebo Event Rate %

Hazard Ratio (95% CI)

How Supplied/Storage and Handling

Losartan Potassium Tablets USP

25 mg tablets are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 277” on one side and plain on the other side.

NDC 0054-0123-22: Bottle of 90 Tablets

50 mg tablets are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 125” on one side and scored on the other side.

NDC 0054-0124-22: Bottle of 90 Tablets

100 mg tablets are supplied as round, green film coated, biconvex, beveled-edge tablets; debossed with product identification “54 357” on one side and plain on the other side.

NDC 0054-0125-22: Bottle of 90 Tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Keep container tightly closed. Protect from light.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling ( Patient Information ).

Advise female patients of childbearing age about the consequences of exposure to Losartan during pregnancy. Discuss treatment options with women planning to become pregnant. Tell patients to report pregnancies to their physicians as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] .

Advise patients receiving Losartan not to use potassium supplements or salt substitutes containing potassium without consulting their healthcare provider [see Drug Interactions (7.1) ] .

Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724

Revised May 2016

PATIENT INFORMATION

Losartan Potassium Tablets USP (loe SAR tan)

Read the Patient Information that comes with Losartan before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition and treatment.

What is the most important information I should know about Losartan?

• Losartan can cause harm or death to an unborn baby. • Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. • If you get pregnant while taking Losartan, tell your doctor right away.

What is Losartan?

Losartan is a prescription medicine called an angiotensin receptor blocker (ARB). It is used:

• Alone or with other blood pressure medicines to lower high blood pressure (hypertension). • To lower the chance of stroke in patients with high blood pressure and a heart problem called left ventricular hypertrophy. Losartan may not help Black patients with this problem. • To slow the worsening of diabetic kidney disease (nephropathy) in patients with type 2 diabetes who have or had high blood pressure.

Losartan has not been studied in children less than 6 years old or in children with certain kidney problems.

High Blood Pressure (hypertension). Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. Losartan can help your blood vessels relax so your blood pressure is lower.

Left Ventricular Hypertrophy (LVH) is an enlargement of the walls of the left chamber of the heart (the heart’s main pumping chamber). LVH can happen from several things. High blood pressure is the most common cause of LVH.

Type 2 Diabetes with Nephropathy. Type 2 diabetes is a type of diabetes that happens mainly in adults. If you have diabetic nephropathy it means that your kidneys do not work properly because of damage from the diabetes.

Who should not take Losartan?

• Do not take Losartan if you are allergic to any of the ingredients in Losartan. See the end of this leaflet for a complete list of ingredients in Losartan. • Do not take Losartan if you have diabetes and are taking a medicine called aliskiren to reduce blood pressure.

What should I tell my doctor before taking Losartan?

Tell your doctor about all of your medical conditions including if you:

• Are pregnant or planning to become pregnant. See “What is the most important information I should know about Losartan?” • Are breastfeeding. It is not known if Losartan passes into your breast milk. You should choose either to take Losartan or breastfeed, but not both. • Are vomiting a lot or having a lot of diarrhea • Have liver problems • Have kidney problems

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Losartan and certain other medicines may interact with each other. Especially tell your doctor if you are taking:

• potassium supplements • salt substitutes containing potassium • water pills (diuretics) • lithium (a medicine used to treat a certain kind of depression) • medicines used to treat pain and arthritis, called non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors • other medicines to reduce blood pressure

How should I take Losartan?

• Take Losartan exactly as prescribed by your doctor. Your doctor may change your dose if needed. • Losartan can be taken with or without food. • If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time. • If you take too much Losartan, call your doctor or Poison Control Center, or go to the nearest hospital emergency room right away.

What are the possible side effects of Losartan?

Losartan may cause the following side effects that may be serious:

• Injury or death of unborn babies. See “What is the most important information I should know about Losartan?” • Allergic reaction. Symptoms of an allergic reaction are swelling of the face, lips, throat or tongue. Get emergency medical help right away and stop taking Losartan. • Low blood pressure (hypotension). Low blood pressure may cause you to feel faint or dizzy. Lie down if you feel faint or dizzy. Call your doctor right away. • For people who already have kidney problems, you may see a worsening in how well your kidneys work. Call your doctor if you get swelling in your feet, ankles, or hands, or unexplained weight gain. • High blood levels of potassium

The most common side effects of Losartan in people with high blood pressure are:

• “colds” (upper respiratory infection) • dizziness • stuffy nose • back pain

The most common side effects of Losartan in people with type 2 diabetes with diabetic kidney disease are:

• diarrhea • tiredness • low blood sugar • chest pain • high blood potassium • low blood pressure

Tell your doctor if you get any side effect that bothers you or that won’t go away.

This is not a complete list of side effects. For a complete list, ask your doctor or pharmacist.

How do I store Losartan?

• Store Losartan potassium tablets at 68°to 77°F (20°C to 25°C). • Keep Losartan in a tightly closed container that protects the medicine from light. • Keep Losartan and all medicines out of the reach of children.

General information about Losartan

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Losartan for a condition for which it was not prescribed. Do not give Losartan to other people, even if they have the same symptoms that you have. It may harm them.

This leaflet summarizes the most important information about Losartan. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Losartan that is written for health professionals.

What are the ingredients in Losartan?

Active ingredients. Losartan potassium USP

Inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, Opadry II (Green) and pregelatinized starch. Opadry II (Green) contains D&C Yellow #10, FD&C Blue #2, hypromellose, lactose monohydrate, polyethylene glycol, titanium dioxide and triacetin.

Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724

Revised May 2016

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

Gastrodine, Gastrodine

Gastrodin

Gastrodin is the most important and effective ingredient extracted from Chinese natural herbal Gastrodia elata. Gastrodin (30, 40, and 60 mM) significantly attenuates levels of neurotoxic proinflammatory mediators and proinflammatory cytokines by inhibition of the NF-kappaB signaling pathway and phosphorylation of MAPKs in LPS-stimulated microglial cells. [1] However, It also upregulates the phosphatidylinositol 3-kinase (PI3-K)/Akt signaling, resulting in the inhibitory effects NF-kappaB and MAPKs activation in H9c2 cardiomyocytes. [2]

Gastrodin at 5 mg/kg can improve cycloheximide - and apomorphine-induced amnesia, but not scopolamine-induced acquisition impairment in rats. Thus, GAS can facilitate memory consolidation and retrieval, but not acquisition. [3] LD50: Mice >1000mg/kg (i. v.) [4]

Related Others Products

CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.

GKT137831 is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with K i of 110 nM and 140 nM, respectively. Phase 2.

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. Phase 1.

Puromycin 2HCl is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

Cyclosporin A is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA.

Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 ?M in a cell-free assay.

Calcitriol is the hormonally active form of vitamin D.

Ribavirin, a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.

BAPTA-AM is a selective, membrane-permeable calcium chelator.

Diclofenac - Woman S Health, D-Fenac

Diclofenac is used to treat pain or inflammation caused by arthritis or ankylosing spondylitis. Diclofenac may also be used for purposes other than those listed in this medication guide.

Use Diclofenac as directed by your doctor.

Take Diclofenac by mouth with or without food. Ask your health care provider any questions you may have about how to use Diclofenac.

Drug Class and Mechanism

Diclofenac is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Diclofenac works by reducing hormones that cause inflammation and pain in the body.

If you miss a dose of Diclofenac, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Store Diclofenac at room temperature between 68 and 77 degrees F (20 and 25 degrees C) in a tightly closed container. Brief periods at temperatures of 59 to 86 degrees F (15 to 30 degrees C) are permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Diclofenac out of the reach of children and away from pets.

Do not use Diclofenac if:

you are allergic to any ingredient in Diclofenac; you have had a severe allergic reaction (e. g. severe rash, hives, breathing difficulties, dizziness) to another NSAID (e. g. ibuprofen, naproxen, celecoxib) or aspirin. Contact your doctor or health care provider right away if any of these apply to you.

Important : Diclofenac may cause dizziness or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Diclofenac with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it. Before you start any new medicine, check the label to see if it has D-fenac or another nonsteroidal anti-inflammatory drug (NSAID) medicine in it too. If it does or if you are not sure, check with your doctor or pharmacist. Diclofenac should not be used in children; safety and effectiveness in children have not been confirmed. Pregnancy and breast-feeding: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Diclofenac while you are pregnant. It is not known if Diclofenac is found in breast milk. Do not breast-feed while using Diclofenac.

Possible Side Effects

Check with your doctor if any of these most common side effects persist or become bothersome:

burning or stinging; discharge; eye redness, irritation, or itching. Seek medical attention right away if any of these severe side effects occur:

severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred or distorted vision; eye infection; eyelid swelling or redness; sensitivity to glare or light.

Diclofenac is to be used only by the patient for whom it is prescribed. Do not share it with other people. If your symptoms do not improve or if they become worse, check with your doctor.

Global Beer Packaging Market To Grow % By 2020 - Key Vendors - Kwes Newswest 9, Rexan

Global Beer Packaging Market to Grow 4.45% by 2020 - Key Vendors - KWES NewsWest 9 / Midland, Odessa, Big Spring, TX: newswest9.com |

DUBLIN --(BUSINESS WIRE)

Research and Markets has announced the addition of the "Global Beer Packaging Market 2016-2020" report to their offering.

The report forecasts the global beer packaging market to grow at a CAGR of 4.45% during the period 2016-2020. It has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The global beer packaging market shows some growth potential because of the emergence of certain trends. One such trend is the introduction of pet beer bottles. Beer packaged in PET have a shelf life of 5-6 months. Nevertheless, to minimize the risk of spoilage, monolayer bottles are used to incorporate an O2 scavenger to increase the shelf life.

According to the report, one of the main factors that impact the market affirmatively is recycling benefits of steel and glass. Unlike plastic and other packaging materials, glass is 100% recyclable. Glass is made from natural minerals such as silica in the form of sand, soda ash, and limestone. This renewable resource does not contain chemicals that can leach into the material inside the containers and is easily recycled.

Further, the report states that particular challenges restrict the growth of the global beer packaging market. One such barrier is fluctuation in energy cost. Glass packaging operations require a continuous supply of energy, primarily natural gas, fuel oil, and electrical power.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market opportunity assessment for different types of beer packaging materials

PART 07: Market segmentation by material

PART 08: Geographical segmentation

PART 09: Market drivers

PART 10: Impact of drivers

PART 11: Market challenges

PART 12: Impact of drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

Research and Markets Laura Wood, Senior Manager press@researchandmarkets. com For E. S.T Office Hours Call 1-917-300-0470 For U. S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U. S. Fax: 646-607-1907 Fax (outside U. S.): +353-1-481-1716

Copyright Business Wire 2016

This article was originally distributed via Business Wire. Business Wire, Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc. com

[ 1 2 3 4 5 6 7 8 9 10 13 ]